复方人参皂甙纳米乳的制备及其免疫增强作用的研究
|
摘要
目的：本研究通过纳米技术将人参皂甙（GS）和盐酸左旋咪唑（LH）组合成复方人参皂甙（GS-LH-NE），对其处方组成、质量性能、生物安全性以及免疫增强作用进行研究，旨在提高GS和LH稳定性的同时，开发一种复方免疫增强剂，减少LH用量，从而降低其毒副作用和药物残留。
方法：（1）样品用甲醇超声处理后，过树脂将GS和LH分离，建立GS-LH-NE药物含量检测方法。（2）利用伪三元相图考察不同纳米乳体系的形成情况，根据纳米乳区大小、纳米乳稳定性以及对药物的溶解能力，筛选出GS-LH-NE药用空白纳米乳配方；然后通过脾淋巴细胞增殖和单核巨噬细胞碳廓清试验，研究不同含药量纳米乳对免疫抑制小鼠的免疫增强作用，从中筛选出免疫增强作用较好的含药纳米乳作为GS-LH-NE处方，并对其进行质量评价。（3）通过家兔皮肤和肌肉刺激试验、小鼠急性毒性试验，考察GS-LH-NE生物安全性。（4）将免疫抑制小鼠分为：正常对照组、模型对照组、空白纳米乳组、LH-NE组、GS-NE组、GS-LH水溶液组、GS-LH-NE高、中、低剂量组，对其细胞免疫、体液免疫和非特异性免疫的相关指标进行检测，研究GS-LH-NE中GS和LH合用的免疫增强效果。（5）将卵清白蛋白（OVA）免疫小鼠分为：正常对照组、OVA对照组、空白纳米乳组、LH-NE组、GS-NE组、GS-LH水溶液组、GS-LH-NE高、中、低剂量组，对其血清抗体及其亚类水平、脾淋巴细胞增殖活性、脾细胞因子产生、NK细胞活性进行检测，研究GS-LH-NE灌胃对抗原免疫的增强作用。（6）从脾淋巴细胞增殖、脾淋巴细胞因子产生以及腹腔巨噬细胞能量代谢、吞噬活性及其效应分子产生等方面，研究GS-LH-NE体外对小鼠主要免疫细胞的作用。
结果：（1）比色-分光光度法测GS含量：平均回收率及其RSD分别为98.86%和0.38％，重复性试验RSD为0.46%，日内和日间精密度RSD分别为0.73%和2.38%；高效液相色谱法测LH含量：平均回收率及其RSD分别为99.02%和0.40％，重复性试验峰面积和保留时间的RSD分别为0.34%和0.77%，日内和日间精密度RSD分别为1.01%和2.03%。（2）GS-LH-NE处方为Solutol HS-15/甘油/PEG400/肉豆蔻酸异丙酯/蒸馏水（质量比为25.33:10.14:2.53:6:56），GS和LH含量分别为30.15mg/mL和30.04mg/mL。它是黄色透明O/W纳米乳，液滴呈球形，平均粒径为23.08nm，粒度分散指数为0.237，浊点为75.4℃，pH为5.67；稳定性好，有效期为18个月。（3）GS-LH-NE一次性或多次用药对完整皮肤和破损皮肤均无刺激；GS-LH-NE对股四头肌刺激反应级最高与最低之差小于2，刺激反应总分为2；GS-LH-NE对小鼠灌胃半数致死量为402.85mg/kg。（4）GS-LH-NE对免疫抑制小鼠免疫增强作用的研究GS-LH-NE中剂量组脾脏指数和胸腺指数与模型对照组比较均显著升高；较LH-NE组分别显著增加56.71%和52.76%；较GS-NE组分别显著增加52.98%和56.70%；较GS-LH水溶液组分别显著增加21.23%和20.63%；与高、低剂量比较均显著升高。GS-LH-NE中剂量组迟发型超敏反应耳重差和ConA诱导脾淋巴细胞增殖的刺激指数与模型对照组比较均显著升高；较LH-NE组分别显著增加43.02%和44.27%；较GS-NE组分别显著增加46.88%和47.66%；较GS-LH水溶液组分别显著增加18.50%和18.13%；与高、低剂量组比较均显著升高。GS-LH-NE中剂量组LPS诱导脾淋巴细胞增殖的刺激指数、血清溶血素水平和抗体形成细胞水平与模型对照组比较均显著升高；较LH-NE组分别显著增加41.27%、64.39%和41.88%；较GS-NE组分别显著增加35.88%、51.81%和39.17%；较GS-LH水溶液组分别显著增加16.34%、24.01%和22.75%；与高、低剂量组比较均显著升高。GS-LH-NE中剂量组单核巨噬细胞吞噬指数、腹腔巨噬细胞吞噬率和吞噬指数、血清溶菌酶水平和脾NK细胞杀伤率与模型对照组比较均显著升高；较LH-NE组分别显著增加33.97%、43.32%、38.46%、39.12%和36.49%；较GS-NE组分别显著增加37.80%、47.22%、44.00%、44.85%和40.69%；较GS-LH水溶液组分别显著增加14.84%、20.87%、18.03%、16.79%和14.96%；与高、低剂量组比较均显著升高。（5）GS-LH-NE对OVA免疫小鼠免疫增强作用的研究GS-LH-NE中剂量组IgG、IgG1和IL-4水平与OVA对照组和低剂量组比较均显著升高；与GS-NE组、GS-LH水溶液组、高剂量组比较均有所升高，但差异均不显著；较LH-NE组分别显著增加31.09%、45.63%和67.62%。GS-LH-NE中剂量组IgG2a和IFN-γ水平与OVA对照组比较均显著升高；较LH-NE组分别显著增加32.75%和40.94%；较GS-NE组分别显著增加34.46%和49.59%；较GS-LH水溶液组分别显著增加11.27%和11.90%；与高、低剂量组比较均显著升高。GS-LH-NE中剂量组ConA、OVA诱导脾淋巴细胞增殖的刺激指数和脾NK细胞活性与OVA对照组均显著升高；较LH-NE组分别显著增加35.96%、39.07%和31.44%；较GS-NE组分别显著增加39.64%、35.48%和36.16%；较GS-LH水溶液组分别显著增加11.91%、15.38%和16.40%；与高、低剂量组比较均显著升高。GS-LH-NE中剂量组LPS诱导脾淋巴细胞增殖的刺激指数与OVA对照组和低剂量组比较显著升高；较LH-NE组显著增加30.41%；与GS-NE组、GS-LH水溶液组和高剂量组比较有所升高，但差异不显著。（6）GS-LH-NE体外对脾淋巴细胞的作用：GS-LH-NE在3.13～12.50μg/mL既能单独又能协同ConA或LPS显著促进脾淋巴细胞增殖，促进脾淋巴细胞产生IL-2和IFN-γ，并且GS-LH-NE在3.13和6.25μg/mL时对脾淋巴细胞免疫功能的增强作用显著强于GS-LH水溶液。GS-LH-NE体外对腹腔巨噬细胞的作用：GS-LH-NE在1.57～6.25μg/mL能显著提高巨噬细胞的能量代谢水平和吞噬活性，促进巨噬细胞产生NO和IL-1β，并且GS-LH-NE在1.57μg/mL时对巨噬细胞免疫功能的增强作用显著强于GS-LH水溶液。
结论：（1）GS和LH含量检测方法的回收率、重复性和精密度均能满足要求，为GS-LH-NE的制备及其质量评价提供了可靠的质检方法。（2）GS-LH-NE处方为Solutol HS-15/甘油/PEG400/肉豆蔻酸异丙酯/蒸馏水（质量比为25.33:10.14:2.53:6:56），GS和LH含量分别为30.15mg/mL和30.04mg/mL，是黄色透明的水包油纳米乳，平均粒径为23.08nm，有效期为18个月。（3）GS-LH-NE对皮肤和肌肉无刺激，对小鼠灌胃半数致死量为402.85mg/kg。（4）GS-LH-NE中GS和LH合用能协同增强免疫抑制小鼠的细胞免疫、体液免疫和非特异性免疫功能，并且其免疫增强作用显著强于GS-LH水溶液；其免疫增强作用和其剂量呈“钟罩”型量效关系。（5）GS-LH-NE灌胃能诱导OVA免疫小鼠产生Th1/Th2混合型免疫反应，增强其细胞免疫、体液免疫以及NK细胞活性；其免疫增强作用和剂量呈“钟罩”型量效关系。GS-LH-NE对细胞免疫和NK细胞活性的增强作用显著强于LH-NE、GS-NE和GS-LH水溶液；对体液免疫的增强作用显著强于LH-NE，较GS-NE和GS-LH水溶液有所增强，但无统计学意义。（6）GS-LH-NE在一定浓度范围内能增强淋巴细胞和巨噬细胞的免疫功能，并且其作用显著强于GS-LH水溶液。
GS-LH-NE是一种稳定、安全、有效的复方免疫增强剂，提高了药物的免疫增强效果，有助于减少LH用量，从而降低其毒副作用和药物残留，可用于增强免疫低下机体的免疫功能和抗原的免疫效果。
Objective: To improve the stability of ginsenoside (GS) and levamisole hydrochloride(LH), and develop an immunostimulants which can be used to be used to reduce the dosageof LH, thereby reducing its toxic side effects and drug residues, GS and LH were combinedinto compound ginsenoside and levamisole hydrochloride nanoemulsion (GS-LH-NE)through nanotechnology. And its prescription composition, quality performance, biologicalsafety and immunological enhancement effect were systematically studied.
Methods:(1) Samples were treated with methanol under ultrasonic emulsion breakingand passed through the resin column to separate GS and LH to establish the analyticalmethod for determining the drug content of GS-LH-NE, which would be used in thepreparation and quality evaluation of GS-LH-NE.(2) Pseudo-ternary phase diagram was usedto study the formation of blank nanoemulsion systems with different components. Accordingto the nanoemulsion region size, the stability of blank nanoemulsion and the drug solubilityin it, the optimum medicinal blank nanoemulsion was screened out to preparate GS-LH-NE.The enhancement effect of nanoemulsions containing different content of drugs on theimmunologic function of immunosuppressive mice were studied through the tests of spleniclymphocytes proliferation and monocyte-macrophage carbon clearance, and the drugnanoemulsion with better immunologic enhancement effect was screened out for ascertain theprescription composition of GS-LH-NE. The quality performance of GS-LH-NE wassystematically studied.(3) The biological safety of GS-LH-NE was evaluated through rabbitskin irritation test, muscle irritation test and intragastric acute toxicity test in mice.(4)Immunosuppressive mice were divided into: normal control group, model control group,blank nanoemulsion group, LH-NE group, GS-NE group, GS-LH solution group, GS-LH-NEhigh dose group, GS-LH-NE middle dose group, GS-LH-NE low dose group. The immuneparameters correlated with cellular, humoral and nonspecific immunity were investigated tostudy the effect of GS and LH combination in GS-LH-NE on the immune function of lowimmune function animals.(5) Mice immunized with ovalbumin were divided into: normalcontrol group, ovalbumin control group, blank nanoemulsion group, LH-NE group, GS-NE group, GS-LH solution group, GS-LH-NE high dose group, GS-LH-NE middle dose group,GS-LH-NE low dose group. The immune parameters of mice, such as the level of serumantigen specific antibody and its subclasses, the proliferation activity of splenic lymphocyte,the cytokine production of splenocytes and the killing activity of NK cells on YAC-1, wereinvestigated to study the effect of oral administration with GS-LH-NE on the immunefunction of antigen or vaccine immunized animals.(6) The effect of GS-LH-NE on micesplenic lymphocytes and peritoneal macrophages were studied in vitro through spleniclymphocytes proliferation and its cytokine production, the energy metabolism level andphagocytic activity of peritoneal macrophages and its effector molecules production.
Results:(1) Colorimetric-spectrophotometry method was used to determine the contentof GS, which showed that the average recovery rate was98.86%, RSD of the averagerecovery rate was0.38%, RSD of the repeatability test was0.46%, RSD of the within-dayprecision was0.73%, and RSD of the day-to-day precision was2.38%. High performanceliquid chromatograph method was used to determine the content of LH, which showed thatthe average recovery rate was99.02%, RSD of the average recovery rate was0.40%, RSD ofthe peak area in the repeatability test was0.34%, RSD of the retention time in therepeatability test was0.77%, RSD of the within-day precision was1.01%, and RSD of theday-to-day precision was2.03%.(2) The optimal prescription composition of GS-LH-NE wasSolutol HS-15/glycerol/PEG400/IPM/distilled water (with the mass ratio of25.33:10.14:2.53:6:56), in which the content of GS and LH were30.15mg/mL and30.04mg/mL, respectively. GS-LH-NE was a yellow transparent O/W nanoemulsion, which hadspherical droplets with the average particle size of23.08nm and the particle dispersion indexof0.237. And its cloud point and pH value were75.4℃and5.67, respectively. It had goodstability and was valid for18months.(3) Both single and multiple dosing of GS-LH-NE didnot show obvious irritation on the unbroken and broken rabbit skins. The difference betweenthe maximum and minimum irritation response of GS-LH-NE on the rabbit muscle was lessthan2, and the total irritation score was2, which showed that GS-LH-NE could be used forintramuscular injection. The gavage LD50of GS-LH-NE in mice was402.85mg/kg (4) Theimmunological enhancement effect of GS-LH-NE on the immunosuppressive mice thespleen index and thymus index in GS-LH-NE middle dose group were significantly higherthan model control group; were significantly increased by56.71%and52.76%than LH-NEgroup, respectively; were significantly increased by52.98%and56.70%than GS-NE group,respectively; were significantly increased by21.23%and20.63%than GS-LH solution group,respectively; were significantly higher than GS-LH-NE high dose group and low dose group,respectively. The ear weight difference of delayed-type hypersensitivity and the stimulation index of splenic lymphocytes proliferation induced by ConA in GS-LH-NE middle dosegroup were significantly higher than model control group; were significantly increased by43.02%than44.27%than LH-NE group, respectively; were significantly increased by46.88%and47.66%than GS-NE group, respectively; were significantly increased by18.50%and18.13%than GS-LH solution group, respectively; were significantly higher thanGS-LH-NE high dose group and low dose group, respectively. The stimulation index ofsplenic lymphocytes proliferation induced by LPS, the level of serum hemolysin and the levelof splenic antibody forming cell in GS-LH-NE middle dose group were significantly higherthan model control group; were significantly increased by41.27%,64.39%and41.88%thanLH-NE group, respectively; were significantly increased by35.88%,51.81%and39.17%than GS-NE group, respectively; were significantly increased by16.34%,24.01%and22.75%than GS-LH solution group, respectively; were significantly higher than GS-LH-NEhigh dose group and low dose group, respectively. The phagocytic index of monocytemacrophage, the phagocytic rate and phagocytic index of peritoneal macrophage, the level ofserum lysozyme and the activity of splenic NK cells in GS-LH-NE middle dose group weresignificantly higher than model control group; were significantly increased by33.97%,43.32%,38.46%,39.12%and36.49%than LH-NE group, respectively; were significantlyincreased by37.80%,47.22%,44.00%,44.85%and40.69%than GS-NE group, respectively;were significantly increased by14.84%,20.87%,18.03%,16.79%and14.96%than GS-LHsolution group, respectively; were significantly higher than GS-LH-NE high dose group andlow dose group, respectively.(5) The immunological enhancement effect of GS-LH-NE onthe ovalbumin-immunized mice the level of IgG, IgG1and IL-4in GS-LH-NE middledose group were significantly higher than ovalbumin control group and GS-LH-NE low dosegroup, respectively; were significantly increased by31.09%,45.63%and67.62%thanLH-NE group, respectively; were above GS-NE group (P＞0.05), GS-LH solution group (P＞0.05) and GS-LH-NE high dose group (P＞0.05). The level of IgG2a and IFN-γ inGS-LH-NE middle dose group were significantly higher than ovalbumin control group; weresignificantly increased by32.75%and40.94%than LH-NE group, respectively; weresignificantly increased by34.46%and49.59%than GS-NE group, respectively; weresignificantly increased by11.27%and11.90%than GS-LH solution group, respectively; weresignificantly higher than GS-LH-NE high dose group and low dose group, respectively. Thestimulation index of splenic lymphocytes proliferation induced by ConA and ovalbumin andthe activity of splenic NK cells in GS-LH-NE middle dose group were significantly higherthan ovalbumin control group; were significantly increased by35.96%,39.07%and31.44%than LH-NE group, respectively; were significantly increased by39.64%,35.48%and 36.16%than GS-NE group, respectively; were significantly increased by11.91%,15.38%and16.40%than GS-LH solution group, respectively; were significantly higher thanGS-LH-NE high dose group and low dose group, respectively. The stimulation index ofsplenic lymphocytes proliferation induced by LPS in GS-LH-NE middle dose group wassignificantly higher than ovalbumin control group and GS-LH-NE low dose group,respectively; was significantly increased by30.41%than LH-NE group; was above GS-NEgroup (P＞0.05), GS-LH solution group (P＞0.05) and GS-LH-NE high dose group (P＞0.05).(6) The effect of GS-LH-NE on the splenic lymphocytes of mice3.13～12.50μg/mL GS-LH-NE could directly promote the proliferation of splenic lymphocytes (P＜0.05or P＜0.01);3.13～12.50μg/mL GS-LH-NE could promote the proliferation of spleniclymphocytes induced by ConA or LPS (P＜0.05or P＜0.01);3.13～12.50μg/mLGS-LH-NE could promote the splenic lymphocytes induced by ConA to produce the cytokineIL-2and IFN-γ (P＜0.05or P＜0.01); And the immunologic enhancement effect of3.13and6.25μg/mL GS-LH-NE on the splenic lymphocytes was significantly stronger than GS-LHaqueous solution. The effect of GS-LH-NE on the peritoneal macrophages of mice1.57～6.25μg/mL GS-LH-NE could improved the energy metabolism level and thephagocytic activity of macrophages（P＜0.05or P＜0.01），promote the macrophages toproduce NO and IL-1β (P＜0.05or P＜0.01); And the immunologic enhancement effect of1.57μg/mL GS-LH-NE on the macrophages was significantly stronger than GS-LH aqueoussolution.
Conclusion:(1) The established analytical methods for determining the content of GSand LH possess high recovery rate, good repetitiveness and good precision，which can beused for the preparation and quality evaluation of GS-LH-NE.(2) The prescriptioncomposition of GS-LH-NE was Solutol HS-15/glycerol/PEG400/IPM/distilled water (withthe mass ratio of25.33:10.14:2.53:6:56), in which the content of GS and LH were30.15mg/mL and30.04mg/mL, respectively. GS-LH-NE was yellow transparent oil in waternanoemulsion, which has the spherical droplets with a average particle size of23.08nm andthe pH value of5.67. It had good stability and was valid for18months.(3) GS-LH-NE hadno obvious irritation on skin and muscle. And the gavage LD50of GS-LH-NE in mice was402.85mg/kg.(4) The combination of GS and LH in GS-LH-NE can work together toenhance the cellular immunity, humoral immunity and nonspecific immunity ofimmunosuppressive mice, which is significantly stronger than the effect of GS-LH aqueoussolution, and shows a “Bell” dose-effect relationship.(5) Oral administration of GS-LH-NEcan promote the ovalbumin-immunized mice to produce a mixed Th1/Th2type immuneresponse, enhance its cellular immunity, humoral immunity and the activity of NK cells, which shows a “Bell” dose-effect relationship. The immunologic enhancement effect ofGS-LH-NE on the cellular immunity and the activity of NK cells of ovalbumin-immunizedmice are significantly stronger than LH-NE, GS-NE and GS-LH solution. Its humoralimmune enhancement is significantly stronger than LH-NE, but compared to GS-NE andGS-LH aqueous solution, its humoral immune enhancement has been enhanced, but there isno significant difference.(6) GS-LH-NE with a certain range can enhance the immunefunction of lymphocytes and macrophages, which were significantly stronger than GS-LHaqueous solution.
GS-LH-NE is a stable, safe and effective immunostimulants and can improve theimmunologic enhancement effect of drugs, which indicates that it can reduce the dosage andthe residue of LH. GS-LH-NE can be used to improve the immune function ofimmunosuppressive animals and enhance the immune effect of antigen.
方法：（1）样品用甲醇超声处理后，过树脂将GS和LH分离，建立GS-LH-NE药物含量检测方法。（2）利用伪三元相图考察不同纳米乳体系的形成情况，根据纳米乳区大小、纳米乳稳定性以及对药物的溶解能力，筛选出GS-LH-NE药用空白纳米乳配方；然后通过脾淋巴细胞增殖和单核巨噬细胞碳廓清试验，研究不同含药量纳米乳对免疫抑制小鼠的免疫增强作用，从中筛选出免疫增强作用较好的含药纳米乳作为GS-LH-NE处方，并对其进行质量评价。（3）通过家兔皮肤和肌肉刺激试验、小鼠急性毒性试验，考察GS-LH-NE生物安全性。（4）将免疫抑制小鼠分为：正常对照组、模型对照组、空白纳米乳组、LH-NE组、GS-NE组、GS-LH水溶液组、GS-LH-NE高、中、低剂量组，对其细胞免疫、体液免疫和非特异性免疫的相关指标进行检测，研究GS-LH-NE中GS和LH合用的免疫增强效果。（5）将卵清白蛋白（OVA）免疫小鼠分为：正常对照组、OVA对照组、空白纳米乳组、LH-NE组、GS-NE组、GS-LH水溶液组、GS-LH-NE高、中、低剂量组，对其血清抗体及其亚类水平、脾淋巴细胞增殖活性、脾细胞因子产生、NK细胞活性进行检测，研究GS-LH-NE灌胃对抗原免疫的增强作用。（6）从脾淋巴细胞增殖、脾淋巴细胞因子产生以及腹腔巨噬细胞能量代谢、吞噬活性及其效应分子产生等方面，研究GS-LH-NE体外对小鼠主要免疫细胞的作用。
结果：（1）比色-分光光度法测GS含量：平均回收率及其RSD分别为98.86%和0.38％，重复性试验RSD为0.46%，日内和日间精密度RSD分别为0.73%和2.38%；高效液相色谱法测LH含量：平均回收率及其RSD分别为99.02%和0.40％，重复性试验峰面积和保留时间的RSD分别为0.34%和0.77%，日内和日间精密度RSD分别为1.01%和2.03%。（2）GS-LH-NE处方为Solutol HS-15/甘油/PEG400/肉豆蔻酸异丙酯/蒸馏水（质量比为25.33:10.14:2.53:6:56），GS和LH含量分别为30.15mg/mL和30.04mg/mL。它是黄色透明O/W纳米乳，液滴呈球形，平均粒径为23.08nm，粒度分散指数为0.237，浊点为75.4℃，pH为5.67；稳定性好，有效期为18个月。（3）GS-LH-NE一次性或多次用药对完整皮肤和破损皮肤均无刺激；GS-LH-NE对股四头肌刺激反应级最高与最低之差小于2，刺激反应总分为2；GS-LH-NE对小鼠灌胃半数致死量为402.85mg/kg。（4）GS-LH-NE对免疫抑制小鼠免疫增强作用的研究GS-LH-NE中剂量组脾脏指数和胸腺指数与模型对照组比较均显著升高；较LH-NE组分别显著增加56.71%和52.76%；较GS-NE组分别显著增加52.98%和56.70%；较GS-LH水溶液组分别显著增加21.23%和20.63%；与高、低剂量比较均显著升高。GS-LH-NE中剂量组迟发型超敏反应耳重差和ConA诱导脾淋巴细胞增殖的刺激指数与模型对照组比较均显著升高；较LH-NE组分别显著增加43.02%和44.27%；较GS-NE组分别显著增加46.88%和47.66%；较GS-LH水溶液组分别显著增加18.50%和18.13%；与高、低剂量组比较均显著升高。GS-LH-NE中剂量组LPS诱导脾淋巴细胞增殖的刺激指数、血清溶血素水平和抗体形成细胞水平与模型对照组比较均显著升高；较LH-NE组分别显著增加41.27%、64.39%和41.88%；较GS-NE组分别显著增加35.88%、51.81%和39.17%；较GS-LH水溶液组分别显著增加16.34%、24.01%和22.75%；与高、低剂量组比较均显著升高。GS-LH-NE中剂量组单核巨噬细胞吞噬指数、腹腔巨噬细胞吞噬率和吞噬指数、血清溶菌酶水平和脾NK细胞杀伤率与模型对照组比较均显著升高；较LH-NE组分别显著增加33.97%、43.32%、38.46%、39.12%和36.49%；较GS-NE组分别显著增加37.80%、47.22%、44.00%、44.85%和40.69%；较GS-LH水溶液组分别显著增加14.84%、20.87%、18.03%、16.79%和14.96%；与高、低剂量组比较均显著升高。（5）GS-LH-NE对OVA免疫小鼠免疫增强作用的研究GS-LH-NE中剂量组IgG、IgG1和IL-4水平与OVA对照组和低剂量组比较均显著升高；与GS-NE组、GS-LH水溶液组、高剂量组比较均有所升高，但差异均不显著；较LH-NE组分别显著增加31.09%、45.63%和67.62%。GS-LH-NE中剂量组IgG2a和IFN-γ水平与OVA对照组比较均显著升高；较LH-NE组分别显著增加32.75%和40.94%；较GS-NE组分别显著增加34.46%和49.59%；较GS-LH水溶液组分别显著增加11.27%和11.90%；与高、低剂量组比较均显著升高。GS-LH-NE中剂量组ConA、OVA诱导脾淋巴细胞增殖的刺激指数和脾NK细胞活性与OVA对照组均显著升高；较LH-NE组分别显著增加35.96%、39.07%和31.44%；较GS-NE组分别显著增加39.64%、35.48%和36.16%；较GS-LH水溶液组分别显著增加11.91%、15.38%和16.40%；与高、低剂量组比较均显著升高。GS-LH-NE中剂量组LPS诱导脾淋巴细胞增殖的刺激指数与OVA对照组和低剂量组比较显著升高；较LH-NE组显著增加30.41%；与GS-NE组、GS-LH水溶液组和高剂量组比较有所升高，但差异不显著。（6）GS-LH-NE体外对脾淋巴细胞的作用：GS-LH-NE在3.13～12.50μg/mL既能单独又能协同ConA或LPS显著促进脾淋巴细胞增殖，促进脾淋巴细胞产生IL-2和IFN-γ，并且GS-LH-NE在3.13和6.25μg/mL时对脾淋巴细胞免疫功能的增强作用显著强于GS-LH水溶液。GS-LH-NE体外对腹腔巨噬细胞的作用：GS-LH-NE在1.57～6.25μg/mL能显著提高巨噬细胞的能量代谢水平和吞噬活性，促进巨噬细胞产生NO和IL-1β，并且GS-LH-NE在1.57μg/mL时对巨噬细胞免疫功能的增强作用显著强于GS-LH水溶液。
结论：（1）GS和LH含量检测方法的回收率、重复性和精密度均能满足要求，为GS-LH-NE的制备及其质量评价提供了可靠的质检方法。（2）GS-LH-NE处方为Solutol HS-15/甘油/PEG400/肉豆蔻酸异丙酯/蒸馏水（质量比为25.33:10.14:2.53:6:56），GS和LH含量分别为30.15mg/mL和30.04mg/mL，是黄色透明的水包油纳米乳，平均粒径为23.08nm，有效期为18个月。（3）GS-LH-NE对皮肤和肌肉无刺激，对小鼠灌胃半数致死量为402.85mg/kg。（4）GS-LH-NE中GS和LH合用能协同增强免疫抑制小鼠的细胞免疫、体液免疫和非特异性免疫功能，并且其免疫增强作用显著强于GS-LH水溶液；其免疫增强作用和其剂量呈“钟罩”型量效关系。（5）GS-LH-NE灌胃能诱导OVA免疫小鼠产生Th1/Th2混合型免疫反应，增强其细胞免疫、体液免疫以及NK细胞活性；其免疫增强作用和剂量呈“钟罩”型量效关系。GS-LH-NE对细胞免疫和NK细胞活性的增强作用显著强于LH-NE、GS-NE和GS-LH水溶液；对体液免疫的增强作用显著强于LH-NE，较GS-NE和GS-LH水溶液有所增强，但无统计学意义。（6）GS-LH-NE在一定浓度范围内能增强淋巴细胞和巨噬细胞的免疫功能，并且其作用显著强于GS-LH水溶液。
GS-LH-NE是一种稳定、安全、有效的复方免疫增强剂，提高了药物的免疫增强效果，有助于减少LH用量，从而降低其毒副作用和药物残留，可用于增强免疫低下机体的免疫功能和抗原的免疫效果。
Objective: To improve the stability of ginsenoside (GS) and levamisole hydrochloride(LH), and develop an immunostimulants which can be used to be used to reduce the dosageof LH, thereby reducing its toxic side effects and drug residues, GS and LH were combinedinto compound ginsenoside and levamisole hydrochloride nanoemulsion (GS-LH-NE)through nanotechnology. And its prescription composition, quality performance, biologicalsafety and immunological enhancement effect were systematically studied.
Methods:(1) Samples were treated with methanol under ultrasonic emulsion breakingand passed through the resin column to separate GS and LH to establish the analyticalmethod for determining the drug content of GS-LH-NE, which would be used in thepreparation and quality evaluation of GS-LH-NE.(2) Pseudo-ternary phase diagram was usedto study the formation of blank nanoemulsion systems with different components. Accordingto the nanoemulsion region size, the stability of blank nanoemulsion and the drug solubilityin it, the optimum medicinal blank nanoemulsion was screened out to preparate GS-LH-NE.The enhancement effect of nanoemulsions containing different content of drugs on theimmunologic function of immunosuppressive mice were studied through the tests of spleniclymphocytes proliferation and monocyte-macrophage carbon clearance, and the drugnanoemulsion with better immunologic enhancement effect was screened out for ascertain theprescription composition of GS-LH-NE. The quality performance of GS-LH-NE wassystematically studied.(3) The biological safety of GS-LH-NE was evaluated through rabbitskin irritation test, muscle irritation test and intragastric acute toxicity test in mice.(4)Immunosuppressive mice were divided into: normal control group, model control group,blank nanoemulsion group, LH-NE group, GS-NE group, GS-LH solution group, GS-LH-NEhigh dose group, GS-LH-NE middle dose group, GS-LH-NE low dose group. The immuneparameters correlated with cellular, humoral and nonspecific immunity were investigated tostudy the effect of GS and LH combination in GS-LH-NE on the immune function of lowimmune function animals.(5) Mice immunized with ovalbumin were divided into: normalcontrol group, ovalbumin control group, blank nanoemulsion group, LH-NE group, GS-NE group, GS-LH solution group, GS-LH-NE high dose group, GS-LH-NE middle dose group,GS-LH-NE low dose group. The immune parameters of mice, such as the level of serumantigen specific antibody and its subclasses, the proliferation activity of splenic lymphocyte,the cytokine production of splenocytes and the killing activity of NK cells on YAC-1, wereinvestigated to study the effect of oral administration with GS-LH-NE on the immunefunction of antigen or vaccine immunized animals.(6) The effect of GS-LH-NE on micesplenic lymphocytes and peritoneal macrophages were studied in vitro through spleniclymphocytes proliferation and its cytokine production, the energy metabolism level andphagocytic activity of peritoneal macrophages and its effector molecules production.
Results:(1) Colorimetric-spectrophotometry method was used to determine the contentof GS, which showed that the average recovery rate was98.86%, RSD of the averagerecovery rate was0.38%, RSD of the repeatability test was0.46%, RSD of the within-dayprecision was0.73%, and RSD of the day-to-day precision was2.38%. High performanceliquid chromatograph method was used to determine the content of LH, which showed thatthe average recovery rate was99.02%, RSD of the average recovery rate was0.40%, RSD ofthe peak area in the repeatability test was0.34%, RSD of the retention time in therepeatability test was0.77%, RSD of the within-day precision was1.01%, and RSD of theday-to-day precision was2.03%.(2) The optimal prescription composition of GS-LH-NE wasSolutol HS-15/glycerol/PEG400/IPM/distilled water (with the mass ratio of25.33:10.14:2.53:6:56), in which the content of GS and LH were30.15mg/mL and30.04mg/mL, respectively. GS-LH-NE was a yellow transparent O/W nanoemulsion, which hadspherical droplets with the average particle size of23.08nm and the particle dispersion indexof0.237. And its cloud point and pH value were75.4℃and5.67, respectively. It had goodstability and was valid for18months.(3) Both single and multiple dosing of GS-LH-NE didnot show obvious irritation on the unbroken and broken rabbit skins. The difference betweenthe maximum and minimum irritation response of GS-LH-NE on the rabbit muscle was lessthan2, and the total irritation score was2, which showed that GS-LH-NE could be used forintramuscular injection. The gavage LD50of GS-LH-NE in mice was402.85mg/kg (4) Theimmunological enhancement effect of GS-LH-NE on the immunosuppressive mice thespleen index and thymus index in GS-LH-NE middle dose group were significantly higherthan model control group; were significantly increased by56.71%and52.76%than LH-NEgroup, respectively; were significantly increased by52.98%and56.70%than GS-NE group,respectively; were significantly increased by21.23%and20.63%than GS-LH solution group,respectively; were significantly higher than GS-LH-NE high dose group and low dose group,respectively. The ear weight difference of delayed-type hypersensitivity and the stimulation index of splenic lymphocytes proliferation induced by ConA in GS-LH-NE middle dosegroup were significantly higher than model control group; were significantly increased by43.02%than44.27%than LH-NE group, respectively; were significantly increased by46.88%and47.66%than GS-NE group, respectively; were significantly increased by18.50%and18.13%than GS-LH solution group, respectively; were significantly higher thanGS-LH-NE high dose group and low dose group, respectively. The stimulation index ofsplenic lymphocytes proliferation induced by LPS, the level of serum hemolysin and the levelof splenic antibody forming cell in GS-LH-NE middle dose group were significantly higherthan model control group; were significantly increased by41.27%,64.39%and41.88%thanLH-NE group, respectively; were significantly increased by35.88%,51.81%and39.17%than GS-NE group, respectively; were significantly increased by16.34%,24.01%and22.75%than GS-LH solution group, respectively; were significantly higher than GS-LH-NEhigh dose group and low dose group, respectively. The phagocytic index of monocytemacrophage, the phagocytic rate and phagocytic index of peritoneal macrophage, the level ofserum lysozyme and the activity of splenic NK cells in GS-LH-NE middle dose group weresignificantly higher than model control group; were significantly increased by33.97%,43.32%,38.46%,39.12%and36.49%than LH-NE group, respectively; were significantlyincreased by37.80%,47.22%,44.00%,44.85%and40.69%than GS-NE group, respectively;were significantly increased by14.84%,20.87%,18.03%,16.79%and14.96%than GS-LHsolution group, respectively; were significantly higher than GS-LH-NE high dose group andlow dose group, respectively.(5) The immunological enhancement effect of GS-LH-NE onthe ovalbumin-immunized mice the level of IgG, IgG1and IL-4in GS-LH-NE middledose group were significantly higher than ovalbumin control group and GS-LH-NE low dosegroup, respectively; were significantly increased by31.09%,45.63%and67.62%thanLH-NE group, respectively; were above GS-NE group (P＞0.05), GS-LH solution group (P＞0.05) and GS-LH-NE high dose group (P＞0.05). The level of IgG2a and IFN-γ inGS-LH-NE middle dose group were significantly higher than ovalbumin control group; weresignificantly increased by32.75%and40.94%than LH-NE group, respectively; weresignificantly increased by34.46%and49.59%than GS-NE group, respectively; weresignificantly increased by11.27%and11.90%than GS-LH solution group, respectively; weresignificantly higher than GS-LH-NE high dose group and low dose group, respectively. Thestimulation index of splenic lymphocytes proliferation induced by ConA and ovalbumin andthe activity of splenic NK cells in GS-LH-NE middle dose group were significantly higherthan ovalbumin control group; were significantly increased by35.96%,39.07%and31.44%than LH-NE group, respectively; were significantly increased by39.64%,35.48%and 36.16%than GS-NE group, respectively; were significantly increased by11.91%,15.38%and16.40%than GS-LH solution group, respectively; were significantly higher thanGS-LH-NE high dose group and low dose group, respectively. The stimulation index ofsplenic lymphocytes proliferation induced by LPS in GS-LH-NE middle dose group wassignificantly higher than ovalbumin control group and GS-LH-NE low dose group,respectively; was significantly increased by30.41%than LH-NE group; was above GS-NEgroup (P＞0.05), GS-LH solution group (P＞0.05) and GS-LH-NE high dose group (P＞0.05).(6) The effect of GS-LH-NE on the splenic lymphocytes of mice3.13～12.50μg/mL GS-LH-NE could directly promote the proliferation of splenic lymphocytes (P＜0.05or P＜0.01);3.13～12.50μg/mL GS-LH-NE could promote the proliferation of spleniclymphocytes induced by ConA or LPS (P＜0.05or P＜0.01);3.13～12.50μg/mLGS-LH-NE could promote the splenic lymphocytes induced by ConA to produce the cytokineIL-2and IFN-γ (P＜0.05or P＜0.01); And the immunologic enhancement effect of3.13and6.25μg/mL GS-LH-NE on the splenic lymphocytes was significantly stronger than GS-LHaqueous solution. The effect of GS-LH-NE on the peritoneal macrophages of mice1.57～6.25μg/mL GS-LH-NE could improved the energy metabolism level and thephagocytic activity of macrophages（P＜0.05or P＜0.01），promote the macrophages toproduce NO and IL-1β (P＜0.05or P＜0.01); And the immunologic enhancement effect of1.57μg/mL GS-LH-NE on the macrophages was significantly stronger than GS-LH aqueoussolution.
Conclusion:(1) The established analytical methods for determining the content of GSand LH possess high recovery rate, good repetitiveness and good precision，which can beused for the preparation and quality evaluation of GS-LH-NE.(2) The prescriptioncomposition of GS-LH-NE was Solutol HS-15/glycerol/PEG400/IPM/distilled water (withthe mass ratio of25.33:10.14:2.53:6:56), in which the content of GS and LH were30.15mg/mL and30.04mg/mL, respectively. GS-LH-NE was yellow transparent oil in waternanoemulsion, which has the spherical droplets with a average particle size of23.08nm andthe pH value of5.67. It had good stability and was valid for18months.(3) GS-LH-NE hadno obvious irritation on skin and muscle. And the gavage LD50of GS-LH-NE in mice was402.85mg/kg.(4) The combination of GS and LH in GS-LH-NE can work together toenhance the cellular immunity, humoral immunity and nonspecific immunity ofimmunosuppressive mice, which is significantly stronger than the effect of GS-LH aqueoussolution, and shows a “Bell” dose-effect relationship.(5) Oral administration of GS-LH-NEcan promote the ovalbumin-immunized mice to produce a mixed Th1/Th2type immuneresponse, enhance its cellular immunity, humoral immunity and the activity of NK cells, which shows a “Bell” dose-effect relationship. The immunologic enhancement effect ofGS-LH-NE on the cellular immunity and the activity of NK cells of ovalbumin-immunizedmice are significantly stronger than LH-NE, GS-NE and GS-LH solution. Its humoralimmune enhancement is significantly stronger than LH-NE, but compared to GS-NE andGS-LH aqueous solution, its humoral immune enhancement has been enhanced, but there isno significant difference.(6) GS-LH-NE with a certain range can enhance the immunefunction of lymphocytes and macrophages, which were significantly stronger than GS-LHaqueous solution.
GS-LH-NE is a stable, safe and effective immunostimulants and can improve theimmunologic enhancement effect of drugs, which indicates that it can reduce the dosage andthe residue of LH. GS-LH-NE can be used to improve the immune function ofimmunosuppressive animals and enhance the immune effect of antigen.
引文
包省军,宋小明.2009.人参茎叶皂甙对口蹄疫病毒灭活疫苗免疫后抗体产生的影响,中国兽医学报,29(9):1103～1105.
毕殿洲.1999.药剂学.北京:人民卫生出版社:101.
蔡伟惠,陈小平,金方.2011.微乳型丙泊酚纳米注射液的制备与评价.中国新药杂志,20(13):1170～1173.
曹丽,顾学文,张天一,汪骅.2011.人参皂甙对小鼠腹腔巨噬细胞活性的影响及其作用机制初步探讨.中国免疫学杂志,27(5):423～426.
常雅萍,杨贵贞.1992.几种中药提取物诱生人干扰素.中国实验临床免疫学杂志,4(6):37～40.
常雅萍,吴雅珍,李平亚,宋玉珍,明月,刘金平,霍德胜.2000. G-Rg治疗单疱病毒性角膜炎实验观察.白求恩医科大学学报,26(2):134～136.
陈明侠,徐华丽,于小风,曲绍春,睢大员,李绪文,金永日.2007.20(S)-原人参二醇的抗肿瘤及免疫调节作用研究.中国药师,10(12):1165～1168.
陈曜,陈春山.2010.人参皂甙小分子的生物学作用.临床和实验医学杂志,9(21):1658～1662.
陈木洲,刘延辉,黄姬,江丹娜.2011.酸碱度对人参皂苷提取率及其稳定性影响分析.中国实用医药,6(20):146～147.
程晓耕,赵雪俭,迟宝琦,曹杰,张淑洁,王晓宇,王成,朱燕.2004. IFN和PDS合剂体内抗流感病毒的作用.微生物学杂志,24(5):64～65.
褚秀玲,苏建青,韦旭斌.2010a.细胞病变观察法检测人参皂苷及其衍生物抗马立克氏病病毒的作用.中国畜牧兽医,37(3):179～183.
褚秀玲,苏建青,韦旭斌.2010b.人参皂苷及其衍生物抗马立克氏病毒的作用.畜牧与兽医,42(3):67～71.
褚秀玲,苏建青,韦旭斌.2010c.人参皂苷Rg3体内抗马立克氏病毒的作用.湖北农业科学,49(1):143～146.
储岳峰,李祥瑞,颜新敏,胡元亮.2005.九种中药成分对体外培养小鼠淋巴细胞功能的影响.中国兽医科技,35(11):908～911.
但汉雄,刘翠霞,江南.2003.人参二醇甙对实验动物的免疫促进作用.湖北中医学院学报,5(1):36～38.
傅红燕,任晓斌.1998.血塞通注射液pH值对其主要皂苷成分的影响.广东药学院学报,14(4):284～286.
葛迎春,李晨燕,任慧君,马天舒,刘平.2002.人参皂甙Rh2注射液对荷肝癌(H22)小鼠免疫功能的影响.特产研究,24(3):4～7.
顾立学,燕春义,罗俊生.2007.人参皂苷对小鼠G422胶质瘤免疫功能的影响.辽宁中医杂志,34(4):523～524.
管孝鞠,吴玉章.2001.人用疫苗佐剂研究中存在的问题.中国生化药物杂志,22(4):210～212.
郭志廷,韦旭斌,梁剑平,单提新.2007.人参总皂苷及其衍生物对小鼠淋巴细胞和NK细胞免疫活性的影响.中国兽医学报,27(5):715～718.
韩大良,黄畅,郭少三,周希瑜.2008.人参皂苷Rb1对体外条件下小鼠骨髓间充质干细胞和粒-巨噬系祖细胞增殖的影响.中华中医药学刊,26(6):1192～1193.
胡元亮,刘家国,陈玉库,张宝康,孙祥峰,王效田.2003.中药成分对传染性法氏囊感染细胞的影响.畜牧与兽医,35(12):8～10.
呼显生,马玉敏,马明颖,吴斌,姜成.2005.人参皂甙Rb1对禽流感疫苗的免疫佐剂作用.河南农业科学,(12):79～81.
黄辉,李义,郝向举.2008.左旋咪唑对罗氏沼虾免疫功能及抗病力的影响.淡水渔业,38(4):36～39.
黄琼,杨杏芬,黄俊明,李志,杨明杰,黄建康.2004. CD+69/CD+3比值和左旋咪唑对照在评价保健食品免疫调节作用中的应用研究.中国卫生杂志,14(1):42～44.
贾宁,王汉,郑晶.2011.复方党参提取物对环磷酰胺处理小鼠免疫功能的调节作用.中国实验方剂学杂志,17(17):206～209.
姜建华,张学进,王育丽.2005.人参皂苷对60Co照射小鼠不良反应的影响.浙江中西医结合杂志,15(11):682～683.
姜东平.2008.玉屏风口服液对鸡新城疫和法氏囊病疫苗免疫效果的影响.畜禽业,232(8):50～52.
江兴林,蒋乐龙,胡祥上,王玉爱,田小英,邓伟峰,房华,刘辉.2006.中药白芍对小鼠体液免疫功能影响的探讨.怀化医专学报,5(2):54～55.
蒋蕊,考书娟,徐小娟,徐德武.2011.槲皮素对免疫低下小鼠体液免疫功能的影响.青岛农业大学学报（自然科学版）,28(2):118～120.
焦成美,刘洪卓,金玲宇,张宇,李三鸣.2008.鼻腔给药地西泮微乳的制备及性质考察.中国药剂学杂志,6(4):156～161.
雷萍,关洪全,王昊,韩晓伟,侯殿东,陈殿学.2011.不同产地人参水煎剂对免疫抑制小鼠细胞免疫功能的影响,中国实验方剂学杂志,17(8):218～220.
李春梅,黄永坚.2002.左旋咪唑对鲫鱼血液吞噬细胞活性的影响,黄冈职业技术学院学报,4(3):26～28.
李桂华,乔彦良,魏爱红,遇欣,曹福敏,孙爱玉.2002.左旋咪唑对鸡离体外周血淋巴细胞的作用.山东家禽,(5):14～17.
李静波,张鸿源,马兴原.1992.人参茎叶皂甙与Rb1等单体对病毒复制的影响.白求恩医科大学学报,18(1):24～26.
李静波,王秀清,孙非.1993.人参茎叶皂甙对单纯疱疹病毒感染细胞的保护作用及与cAMP的关系.吉林中医药,1993,(1):41～42.
李凌夫,王曾力,张燕,王雅贤,杨宝华,贾宽,张德山.1996a.人参皂苷-Rc对正常成人外周血NK及LAK细胞活性影响的实验研究.中医药信息,(2):52~54.
李凌夫,王冬,张燕等,王雅贤,杨宝华,贾宽,张德山.1996b.人参皂苷-Re对正常成人外周血LAK和NK细胞活性影响的实验研究.中医药信息,(3):54~55.
李平亚,郝秀华,赵春芳,常雅萍,王博藯,吴浩.2001.人参皂甙-Rg3、-Rb3抗病毒作用的研究.中国老年学杂志,21(5):215～216.
李卫平,陈敏珠.1998.人参皂苷的免疫调节作用．安徽医科大学学报,33(5):348～350.
李晓林,王静凤,田守生,傅佳,赵芹,李冰,薛长湖.2010.海参和鱼翅的营养成分以及对免疫功能调节作用的比较.中国海洋大学学报,41(1-2):65～70.
李玉赜,张连学,姚允怡,齐宪辉,郜玉钢.2011.人参皂苷抗梅花鹿源BVDV研究.安徽农业科学,39(23):14036～14044.
李兆明,姬涛,侯林,田景振.2009.比色法测定保健酒中人参总皂苷含量.吉林中医药,29(5):425～426.
黎阳,张铁军,刘素香,陈常青.2009.人参化学成分和药理研究进展.中草药,40(1):164～166.
梁华平,王正国,田丰群,耽波，陈荣德.1995a.黄芪多糖、人参茎叶皂甙对创伤小鼠血浆及免疫细胞内cAMP、cGMP的影响.中国病理生理杂志,11(6):595～599.
梁华平,王正国,田丰群,耿波,陈荣德.1995b.烧伤后白介素与白介素受体基因表达的变化及人参茎叶皂甙的调节作用.第三军医大学学报,17(5):103～106.
梁华平,王正国,耿波,天风群,罗艳,徐祥.1996.黄芪多糖及人参茎叶皂甙对创伤小鼠免疫器官影响.中医研究,9(2):15～17.
刘安刚,李引乾,孙娇,孙薇薇,赵建乐,俞亚玲,王成龙,姬双双.2011.氟苯尼考纳米乳的制备及品质评价.西北农业学报,20(5):44～49.
刘芬娣,李德全.2010.人参配伍五灵脂人参总皂苷的含量变化规律研究.首都医药,(22):40～41.
刘红樱,葛均波,马晓娟,史大卓.2011.人参皂苷Rb1对氧化型低密度脂蛋白诱导的人单核细胞源树突状细胞免疫成熟的影响.中国中西医结合杂志,31(3):350～354.
刘靖华,陈惠孙,胡德耀,刘良明.2000.人参皂甙对创伤失血性休克免疫功能的调节作用.第三军医大学学报,22(4):324～327.
刘丽芳,张阳德.2010.中药纳米乳研究进展,中医药导报,16(8):112～115.
刘忞,张均田.1996.人参皂甙Rg1对老年大鼠免疫调节作用的机制分析.药学学报,31(2):95～100.
刘素梅,李华岑,韩立,徐银凤,臧合英,张要京,王军红.2010.万乳康中盐酸左旋咪唑含量测定方法的研究.中国兽药杂志,44(2):26～28.
刘伟宏,龚守良,李新民,刘树铮.1994.人参三醇组甙对雄性大鼠免疫器官的辐射防护作用.白求恩医科大学学报,20(1):32～34.
刘轩,魏育林,李波,李亚俊,金恩源,王学静．2001.人参皂苷对脂多糖诱导小鼠肺泡巨噬细胞分泌肿瘤坏死因子的作用及机制探讨．中日友好医院学报，15(2):83～86.
陆振达,耿惠珍.1995.稳定盐酸左旋咪唑注射液PH的试验.现代应用药学,12(6):3～4.
骆艳秋,尹柏双,徐文勇,姜成.2008.人参叶皂甙对鸡免疫功能调节的研究.安徽农业科学,36(1):202～204.
吕梦捷,曾耀英,宋兵.2011.人参皂甙Rb1对小鼠腹腔巨噬细胞体外吞噬及细胞因子和NO分泌的影响.细胞与分子免疫学杂志,27(3):242～245.
毛平,马骏,陈艳艳,虞桂珍,谭梦晖.2006.不同药性补气中药对小鼠脾淋巴细胞增殖及细胞因子分泌的影响.上海中医药大学学报,20(3):49～51.
梅少林,袁红艳,曹湘博,常雅萍,李平亚,刘金萍.2006.人参皂苷Rg3体外抗HSV-1活性与免疫调节效应.吉林大学学报（医学版），32(6):1019～1022.
梅少林,袁红艳,曹湘博,常雅萍,李平亚,刘金萍.2007.人参皂苷Rg3对HSE模型鼠的治疗作用及免疫调节效应.吉林大学学报（医学版），33(1):119～122.
聂奎.1989.左旋咪唑的免疫学药理作用及其应用.国外兽医学-畜禽疾病,(4):1～5.
牛华星,李淑花,张传津.2009.盐酸左旋咪唑-维生素E可溶性粉对鸡免疫功能增强作用研究.山东畜牧兽医,30(8):13～15.
潘维华,刘晓颖,王英平,刘继永.2011.人参皂苷对小鼠脾淋巴细胞和腹腔巨噬细胞免疫活性的影响.特产研究,33(1):16～19.
乔彦良,杨汉春,郭玉璞,盛英霞,马贤本,付兴伦.2000.左旋咪唑对鸡细胞免疫和体液免疫功能的作用.畜牧与兽医,32(2):1～4.
乔彦良,初晓翠,孙爱玉,盛英霞,张妍,贺营,韩治桃,杨汉春,郭玉璞.2001.左旋咪唑对地塞米松预处理鸡免疫功能的影响.兽药与饲料添加剂,6(4):3～5.
曲婷婷,金岩,柳越冬,井欢,刘树权,关洪全,李建春.2006.人参皂苷Rb1、Rg1与5-氟脲嘧啶对荷瘤小鼠免疫功能的影响.中医研究,19(5):16～18.
任杰红,陈林芳,张路晗,程睿.2002.人参皂苷Rg1的免疫促进作用.中药新药与临床药理,13(2):92～93.
苏建青,褚秀玲,韦旭斌.2010.人参皂苷及其衍生物体内抗马立克氏病毒的间接免疫荧光观察与PCR检测.中国兽医学报,30(4):485～488.
田志刚,杨贵贞.1991.人参三醇皂甙促进人淋巴结细胞IFN-γ基因表达.上海免疫学杂志, l1(2):82～84.
田志刚,刘杰,孙汭,李柏青,张捷,张建华.1993.人参三醇型皂甙对IL-6基因的促转录效应.中国药理学通报,9(5):371～372.
肖啸,杨继生,张静,肖焰.2008a.左旋咪唑对仔猪免疫指标的影响.甘肃畜牧兽医,(4):2～4.
肖啸,杨林富,代飞燕,赵辉斌.2008b.左旋咪唑对犬免疫指标的影响.山东畜牧兽医,29(10):6～7.
王斌,李杰芬,胡岳山.2003.人参皂甙对小鼠脾脏树突状细胞增殖的影响.上海免疫学杂志,23(6):381～382.
王德云,胡元亮,孔祥峰,孙峻岭,张宝康,刘家国,夏明龙.2005.中药成分对培养的鸡脾脏淋巴细胞增殖的影响.畜牧兽医学报,36(11):1210～1214.
王鹤尧,郑文婕.2006.左旋咪唑腔给药改变小鼠变应性鼻炎黏膜局部的Thl/Th2免疫应答.中国新药杂志,15(17):1446～1450.
王静凤,李晓林,滕来宾,薛勇,傅佳,赵芹,薛长湖.2011.海参虫草复剂对免疫功能低下小鼠的免疫调节作用.卫生研究,40(2):215～218.
王书全，王晓玉.2010.左旋咪唑对鸡新城疫LaSota疫苗免疫效果的影响.中国家禽,32(19):31～33.
王庭富,孟正木.1999.人参皂甙Rg3对免疫功能的影响．中国药科大学学报,30(2):133～135.
王晓黎,蒋雪涛,李干佐,牟建海.2001.非离子型表面活性剂微乳的基础研究.解放军药学学报,6(17):197～300.
王新卫,杨永珍,王艳.2008.左旋咪唑对新城疫灭活疫苗抗体滴度的影响.中国农学通报24(12):1～3.
王新卫,邹正耀,杨霞,张红英.2009.左旋咪唑影响流感灭活疫苗（H9N2）抗体滴度.中国农学通报,25(20):38～41.
王毅,郝钰,邱全瑛,黄启福.2007.人参皂苷Rg1与Rh1对树突状细胞表达HLA-DR、CD25、CD44、CD54、CD11c及E-selectin的影响.中医中药与免疫,23(1):46～49.
危建安,程志安,温建炫,戴韵峰,莫嘉强.2011.人参多糖与人参皂苷诱导大鼠骨髓间充质干细胞造血细胞因子表达的作用比较.中国中西医结合杂志,31(3):372～375.
魏永俊,潘玉善,苑丽,刘建华,陈玉霞,胡功政,王立业,骈永亮.2010.妥曲珠利纳米乳的研制及其初步质量评价.江西农业学报,22(3):146～149.
吴东东,刘琪.2010.人参皂苷Rg3对环磷酰胺的增效作用.医药导报,29(07):850～853.
吴章怀,秦大莲,岳永花,邓莎,周淼,刘剑.2009.脑舒胶囊对免疫低下小鼠免疫功能的调节作用.时珍国医国药,20(9):2336～2337.
向枭,向勇,冯君,胡美蓉.2002.甲壳素和左旋咪唑对罗非鱼的对比生长试验.饲料工业,23(11):43～45.
谢明权,宋长绪,黄忠.2000.5种免疫增强剂对猪PBMC增殖反应的影响.中国兽医学报,20(5):485～486.
许丹妮,李健,马玉芳,黄一帆.2011.金线莲多糖对免疫抑制小鼠脾淋巴细胞增殖及免疫器官的影响.中兽医医药杂志,13(3):15～17.
许国焕,余进峰,唐峻峰,赵新安,郑莲春.2001.几种促生长剂对中华鳖养殖效果的研究.水利渔业,21(1):33～34.
严铭铭,王旭,钟英杰,李龙云,曲晓波,赵大庆.2006.人参皂苷Rg2注射液制备工艺的研究.中草药,37(5):697～700.
杨帆,陆益,李艳,梁宁生,蒙子卿.2004.复方华蟾胶囊对小鼠免疫功能的影响.中国医院药学杂志,24(8):451～452.
杨帆,席伟,谢裕安,黎远冬,罗小玲,匡志鹏,吴继宁,李蕾.2011.蛤蚧肽对小鼠免疫功能的调节作用.广西医科大学学报,28(3):342～344.
杨贵贞,鲍涛,富宁,耿排力.1983.人参皂甙对体内外免疫调整作用的初步研究.白求恩医科大学学报,9(3):1～7.
张才军，郭民，柳波，后文俊，王玲.2009.人参皂苷Rh1对免疫功能降低小鼠的免疫调节作用研究.昆明医学院学报,30(11):51～54.
张春晶,顾立刚,牛旭艳,王甫,彭桂英.2009.人参皂苷Rg1和Rb1对流感病毒感染细胞的影响及其机制研究.中华微生物学和免疫学杂志,29(10):894～900.
张发亮,叶勇.2008.0.5%伊维菌素微乳剂的研制.安徽农业科学.36(1):231～233.
张华,薛家宾,黄克和,陈兴祥,徐为中.2004.左旋咪唑对正常和受抑制兔体外淋巴细胞转化的影响.江苏农业科学,(5):86～88.
张兰兰,闫明,刘晓东,霍仕霞.2009.驱白巴布期片对小鼠免疫功能的影响.时珍国医国药,20(8):1893～1895.
张勤,叶再元,杜卫东.2003.人参皂甙对腹腔感染大鼠血清白蛋白及白介素-6影响的实验研究.浙江中医学院学报,27(4):66～67.
张日俊,黄燕,佟建民,萨仁娜.1999.饲用左旋咪唑对肉仔鸡免疫功能调节作用的研究.中国畜牧杂志,35(5):5～8.
张锐,徐华丽,于小风,曲绍春,陈明侠,睢大员.2009.20(S)-原人参二醇对荷瘤裸鼠化疗的增效减毒作用.吉林大学学报（医学版）,35(2):195～200.
张善玉,朴惠顺,申英爱.2005.黄芪多糖与人参总皂苷联用的免疫调节作用初步研究.中药房,(16)21:1620～1622.
张松莲.2007.仙人掌多糖免疫调节作用的研究.[硕士论文].湖南：湖南农业大学.
张晓文,宋清,徐志伟.2010.人参茎叶总皂苷对心理应激荷瘤小鼠肿瘤生长及化疗效果的影响.现代食品科技,26(4):348～350.
张霄翔,王艳苹,王玉凤,陈少兵.2009a.瓜蒌皮对环磷酰胺致免疫功能低下小鼠免疫功能的影响.中国药房,20(9):648～650.
张霄翔,王艳苹,王玉凤,陈少兵.2009b.甘寒归肝肾经中药药性研究（Ⅰ）—对免疫功能低下小鼠免疫功能的影响.中华中医药杂志,24(2):240～242.
张瑛,孟建国,王成,申圣丹,王盛民.2010.人参不同制品对小鼠淋巴细胞增殖免疫功能的影响.时珍国医国药,22(4):867～868.
郑晓波,张世华.2000.左旋咪唑对试验兔创伤愈合的影响研究.甘肃畜牧兽医,30(2):20～22.
周才琼,张雨.2008.印度人参根提取物的免疫调节作用.食品科学,29(7):412～415.
周东波,胡成平,梁硕,杨红忠.2007.人参单体皂甙Rh2对非小细胞肺癌患者肺泡巨噬细胞免疫活性的影响.中南大学学报（医学版）,32(5):868～872.
周娅红.2010.人参总皂苷对免疫低下小鼠免疫功能的影响.中国中医急症,19(9):1559～1561.
周英武,彭桂英,顾立刚,殷胜骏.2010.利用生物芯片技术检测人参皂苷Rg1对小鼠树突状细胞功能调控相关基因表达的影响.中国免疫学杂志,26(12):1086～1090.
Akaza H, Yokoyama H, Umeda T, Niijima T.1979. Restoration by levamisole of E-rosette formation andits abrogation by autochthonous serum from patients with bladder cancer. Cancer,43(1):97～100.
Ammar HO, Salama HA, M Ghorab, Mahmoud AA.2009. Nanoemulsion as a potential ophthalmicdelivery system for dorzolamide hydrochloride. AAPS PharmSciTech,10(3):808～819.
Bali V, Ali M, Ali J.2010. Study of surfactant combinations and development of a novel nanoemulsion forminimising variations in bioavailability of ezetimibe. Colloids Surf B Biointerfaces,76(2):410～420.
Batungbacal MR.1993. The effect of levamisole hydrochloride on the immune response of chicens toinfections coryza vaccine. Philippine Journal of veterinary medicine,30(1):27～31.
Bevilaqua MP.1993. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol.11:767～804.
Bonagura VR, Hatam L, DeVoti J, Zeng F, Steinberg BM.1999. Recurrent respiratory papillomatosis:altered CD8(+) T-cell subsets and T(H)1/T(H)2cytokine imbalance. Clin Immunol,93(3):302～311.
Bo i F, Banovi F, uran J, Crni AP.2011. Adjuvant activity of levamisole for experimental F18ac(+)Escherichia coli oral vaccine against porcine post-weaning colibacillosis. Veterinarski Arhiv,81(2):199～209.
Cabaj W, Stankiewicz M, Jonas WE, Moore LG.1995. Levamisole and its influence on the immuneresponse of lambs. Vet Res Commun,19(1):17～26.
Campbell, JB.1995. Saponins. In: Stewart-Tull DES. The theory and practical application of adjuvants.New York: John Wiley&Sons Ltd.:95～127.
Cevc G., Vierl U.2010. Nanotechnology and the transdermal route: A state of the art review and criticalappraisal. J Control Release,141(3):277～299.
Chai JL, Wu YT, Li XQ, Yang B, Chen LS, Shang SC, Lu JJ.2011. Effect of alkane/water ratios on thephase behavior and the solubilization of microemulsion systems containinghexadecyltrimethylammonium bromide. J. Chem. Eng. Data,56(1):48～52.
Chan SH, Simons MJ.1975. Levamisole and lymphocyte responsiveness. Lancet,1(7918):1246～1247.
Chavali SR, Barton LD, Campbell JB.1988. Immunopotentiation by orally-administered Quillaja saponins:effects in mice vaccinated intraperitoneally against rabies. Clin Exp Immunol,74(3):339～343.
Chen LY, Lin YL, Chiang BL.2007. Levamisole enhances immune response by affecting the activation andmaturation of human monocyte-derived dendritic cells. Clin Exp Immunol,151(1):174～181.
Chen XP, Qian LL, Jiang H, Chen JH.2011. Ginsenoside Rg3inhibits CXCR4expression and relatedmigrations in a breast cancer cell line. Int J Clin Oncol,16(5):519～523.
Cheng YJ, Zhang M, Liang QL, Hu P, Wang YM, Frank WJ, Luo GA.2011. Two-steppreparation ofginsenoside-Re, Rb1, Rc and Rb2from the root of Panaxginseng byhigh-performancecounter-currentchromatography. Separation and Purification Technology,77(3):347～354.
Cho JY, Yoo ES, Baik KU, Park MH, Han BH.2001. In vitro inhibitory effect of protopanaxadiolginsenosides on tumor necrosis factor (TNF)-alpha production and its modulation by knownTNF-alpha antagonists. Planta Med,67(3):213～218.
Cho JY, Kim AR, Yoo ES, Baik KU, Park MH.2002. Ginsenosides from Panax ginseng differentiallyregulate lymphocyte proliferation. Planta Med,68(6):497～500.
Confer AW, Adldinger HK.1981. The in vivo effect of levamisole on phytohaemagglutinin stimulation oflymphocytes in normal and Marek's disease virus inoculated chickens. Res Vet Sci,30(2):243～245.
Confer AW, Hall SM, Espe BH.1985. Transient enhancement of the serum antibody response to Brucellaabortus strain19in cattle treated with levamisole. Am J Vet Res,46(12):2440～2443.
Cox JC，Coulter AR.1997. Adjuvants-a classifieation and review of their modes of action. Vaccine,15(1):48～56.
Cuesta A, Esteban MA, Meseguer J.2002. Levamisole is a potent enhancer of gilthead seabream naturalcytotoxic activity. Vet Immunol Immunopathol,89(3-4):169～174.
D'Cruz OJ, Uckun FM.2007. Preclinical evaluation of a dual-acting microbicidal prodrug WHI-07incombination with vanadocene dithiocarbamate in the female reproductive tract of rabbit, pig, and cat.Toxicol Pathol,35(7):910～927.
Diluzio NR.1979. Lysozyme activity: an index of macrophage functional statu. Front Biol,48:447～462.
Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA.1986. Induction by IL1andinterferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule(ICAM-1). J Immunol,137(1):245～254.
Endo S, Kinoshita J, Yoshimatsu K, Kato H, Haga S, Kajiwara T.1998. Intrahepatic lymphocyte analysesand assessment of the effects of levamisole in murine hepatic metastasis model. Anticancer Res,18(2A):907～910.
Fu W, Wei J, Gu J.2006. MEF2C mediats the activation-induced cell death (AICD) of macrophage. CellRes,16(4):377～382.
Gao F, Zhang Z, Bu H, Huang Y, Gao Z, Shen J, Zhao C, Li Y.2011. Nanoemulsion improves the oralabsorption of candesartan cilexetil in rats: Performance and mechanism. J Control Release,149(2):168～174.
Gan L, Gan Y, Zhu CL, Zhang XX, Zhu JB.2009. Novel microemulsion in situ electrolyte-triggered gellingsystem for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results. Int J Pharm,365(1-2):143～149.
Ganta S, Amiji M.2009. Coadministration of paclitaxel and curcumin in nanoemulsion formulations toovercome multidrug resistance in tumor cells. Mol Pharm,6(3):928～939.
Hajnzic TF, Kastelan M, Lukac J, Hajnzic T.1999. Immunocompetent cells and lymphocyte reactivity tomitogens in levamisole-treated brain tumor children. Pediatric Hematology-Oncology,16(4):335～340.
Hashem FM, Shaker DS, Ghorab MK, Nasr M, Ismail A.2011. Formulation, characterization, and clinicalevaluation of microemulsion containing clotrimazole for topical delivery. AAPS PharmSciTech,12(3):879～886.
Hassan AB, Atta AH, Soliman RT.1989. Effect of levamisole hydrochloride on the immune response tonewcastle disease virus vaccine in chickens. Indian Vet J,66:389～394.
Hennessy KJ, Blecha F, Pollmann DS, Kluber EF.1987. Isoprinosine and levamisole immunomodulation inartificially reared neonatal pigs. Am J Vet Res,48(3):477～480.
Hirunpanich V, Sato H.2009. Improvement of cyclosporine A bioavailability by incorporating ethyldocosahexaenoate in the microemulsion as an oil excipient. Eur J Pharm Biopharm,73(2):247～252.
Hoffmann KF, James SL, Cheever AW, Wynn TA.1999. Studies with double cytokine-ceficient mice revealthat highly polarized Th1-and Th2-Type cytokine and antibody responses contribute equally tovaccine-induced immunity to Schistosoma mansoni. J Immunol,163(2):927～938.
Hu S, Concha C, Lin F, Persson Waller K.2003. Adjuvant effect of ginseng extracts on the immuneresponses to immunisation against Staphylococcus aureus in dairy cattle. Vet Immun Immunopathol,91(1):29～37.
Hunter KW, Fischer GW, Sayles PC, Strickland GT.1981. Levamisole: potentiation of primaryimmunoglobulin M antibody responses in suckling rats. Immunopharmacology,3(2):117～127.
Huang YB, Lin YH, Lu TM, Wang RJ, Tsai YH, Wu PC.2008. Transdermal delivery of capsaicinderivative-sodium nonivamide acetate using microemulsions as vehicles. Int J Pharm,349(1-2):206～211.
Huang T, Chen Y, Shou TX, Yang J, Li D.2011. Safety evaluation of diacylglycerol microemulsion inrats/mice. Agricultural Sciences in China,10(7):1117～1124.
Ince S, Kozan E, Kucukkurt I, Bacak E.2010. The effect of levamisole and levamisole+vitamin C onoxidative damage in rats naturally infected with Syphacia muris. Experimental Parasitology,124(4):448～452.
Irwin MR, Holmberg CA, Knight HD, Hjerpe CA.1976. Effects of vaccination infectious bovinerhinotracheitis and simultaneous administration of levamisole on primary humoral responses in calves.Am J Vet Res,37(2):223～226.
Ispir U, Yonar ME.2007. Effects of levamisole on phagocytic activity of rainbow trout (Oncorhynchusmykiss W.). Acta Vet Brno,76(3):493～497.
Jackson LA, Opdebeeck JP.1995. The effect of various adjuvants on the humoral immune response ofsheep and cattle to soluble and membrane midgut antigens of Boophilus microplus. Vet Parasitol,58(1-2):129～141.
Jenkins EM, Hurdle C.1989. Effect of levamisole on parenteral vaccines for swine dysentery. Br Vet J,145(6):565～572.
Jin HL, Li YJ, Ma ZH, Zhang FC, Xie QG, Gu DF, Wang B.2004. Effect of chemical adjuvants on DNAvaccination. Vaccine,22(21-22):2925～2935.
Johnkoski JA, Hsueh CT, Doerr RJ, Cohen SA.1992. Augmentation of the immune response of the murineliver by levamisole. Am J Surg,163(2):202～207.
Kale AA, Patravale VB.2008. Development and evaluation of lorazepam microemulsions for parenteraldelivery. AAPS PharmSciTech,9(3):966～971.
Kang Y, Jin H, Zheng G, Xie Q, Yin J, Yu Y, Xiao C, Zhang X, Chen A, Wang B.2005. The adjuvant effectof levamisole on killed viral vaccines. Vaccine,23(48-49):5543～5550.
Kang JH, Song KH, Woo JK, Park MH, Rhee MH, Choi C, Oh SH.2011. Ginsenoside Rp1from Panaxginseng exhibits anti-cancer activity by down-regulation of the IGF-1R/Akt pathway in breast cancercells. Plant Foods Hum Nutr,66(3):298～305.
Kaya EG, Ozbilge H, Ustundag MB, Torun YA.2011. The effects on immune response of levamisoletreatment following infection of U-937macrophages with Candida albicans. Acta Microbiol ImmunolHung,58(4):279～288.
Kensil CR, Patel U, Lennick M, Marciani D.1991. Separation and characterization of saponins withadjuvant activity from Quillaja saponaria Molina cortex. J Immunol.146(2):431～437.
Kim JY, Germolec DR, Luster MI.1990. Panax ginseng as a potential immunomodulator: studies in mice.Immunopharmacol Immunotoxicol,12(2):257～276.
Kimball ES, Schneider CR, Fisher MC, Clark MC.1992. Levamisole causes differential cytokineexpression by elicited mouse peritoneal macrophages. J Leukoc Biol,52(3):349～356.
Kong M, Park HJ.2011a. Stability investigation of hyaluronic acid based nanoemulsion and its potential astransdermal carrier. Carbohydrate Polymers,83(3):1303～1310.
Kong M, Chen XG, Kweon DK, Park HJ.2011b. Investigations on skin permeation of hyaluronic acidbased nanoemulsion as transdermal carrier. Carbohydrate Polymers,86(2):837～843.
Krakauer T, Oppenheim JJ.1993. IL-1and tumor necrosis factor-alpha each up-regulate both theexpression of IFN-gamma receptors and enhance IFN-gamma-induced HLA-DR expression on humanmonocytes and a human monocytic cell line (THP-1). J Immunol,15;150(4):1205～1211.
Larsen MW, Moser C, Hoiby N, Song Z, Kharazmi A.2004. Ginseng modulates the immune response byinduction of interleukin-12production. APMIS,112(6):369～373.
Lee YS, Chung LS, Lee IR.1997. Activation of multiple effectors pathways of immune system by theanti-neoplastic immunostimulator acidicpolysaccharide ginseng isolated from Panax ginseng.Anticancer Res,17(3):43～47.
Lee EJ, Ko EJ, Lee JW, Rho SW, Ko SY, Shin MK, Min BI, Hong MC, Kim SY, Bae HS.2004.Ginsenoside Rg1enhances CD4+T-cell activities and modulates Th1/Th2differentiation. IntImmunopharmacol,4(2):235～244.
Lee DY, Cho JG, Lee MK, Lee JW, Lee YH, Yang DC, Baek NI.2011. Discrimination of panax ginsengroots cultivated in different areas in korea using HPLC-ELSD and principal component analysis. J.Ginseng Res,35(1):31～38.
Li GF, Guo YG, Zhao DH, Qian PF, Sun JJ, Xiao C, Liang LQ, Wang HF.2006. Effects of levamisole onthe immune response and disease resistance of Clarias fuscus. Aquaculture,253(1-4):212～217.
Li RL, Sakwiwatkul K, Li YT, Hua SH.2009. Enhancement of the immune responses to vaccinationagainst foot-and-mouth disease in mice by oral administration of an extract made from RhizomaAtractylodis Macrocephalae (RAM). Vaccine,27,(15):2094～2098.
Li G.F, Liu LB, Tan YL, Liu LZ, Deng HZ, Wan H, Zhong WZ, Chen SJ.2011. In vitro effect of levamisoleon the cell viability, phagocytosis and respiratory burst of Barbel chub (Squaliobarbus curriculus)macrophages. Aquaculture Nutrition,17: e263～e270.
Li J, Xie ZZ, Tang YB, Zhou JG, Guan YY.2011. Ginsenoside-Rd, a purified component from panaxnotoginseng saponins, prevents atherosclerosis in apoE knockout mice. Eur J Pharmacol,652(1-3):104～110.
Li XR, Yue YT, Zhou YX, Fan YT, Fan C, Huang YQ, Wu F, Liu Y.2011. An oil-free microemulsion forintravenous delivery of diallyl trisulfide: Formulation and evaluation. Int J Pharm,407(1-2):158～166.
Liew FY, Cox FE.1991. Nonspecific defence mechanism: the role of nitric oxide. Immunol Today,12(3):A17～21.
Liu J, Wang S, Liu H, Yang L, Nan G.1995. Stimulatory effect of saponin from Panax ginseng on immunefunction of lymphocytes in the elderly. Mech Ageing Dev,83(1):43～53.
Lu H, Huo X, Zhang Y, Zheng M, Ma M, Zhang H, Jin M, Shen G, Jia L, Ji Y, Li X, Jin K, Jin N.2008.Enhancing effects of the chemical adjuvant levamisole on the DNA vaccine pVIR-P12A-IL18-3C.Microbiol Immunol,52(9):440～446.
MacMicking J, Xie QW, Nathan C.1997. Nitric oxide and macrophage function. Annu Rev Immunol,15:323～350.
Maey DW.1997. Vaccine adjuvants. Semin Vet surg,12:206～211.
Mayer B, Hemmens B.1997. Biosynthesis and action of nitric oxide in mammalian cells. Trends BiochemSci,22(12):477～481.
Misra CK, Das BK, Mukherjee SC.2009. Immune response, growth and survival of Labeo rohitafingerlings fed with levamisole supplemented diets for longer duration. Aquaculture Nutrition,15(4):356～365.
Mulero V., Esteban MA, Munoz J, Meseguer J.1998. Dietary intake of levamisole enhances the immuneresponse and disease resistance of the marine teleost gilthead seabream (Sparus aurataL.). Fish&Shellfish Immunology,8(1):49～62.
Narang G., Kharole MU.1995. Effect of levamisole on the efficacy of turkey herpesvirus vaccine againstMarek's disease. Indian J Vir,11(11):13～22.
Newman MJ, Wu JY, Gardner BH, Anderson CA, Kensil CR, Recchia J, Coughlin RT, Powell MF.1997.Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1gp120using saponinadjuvant(QS-21) supplemented subunit vaccine formulations. Vaccine,15(9):1001～1007.
Nornoo AO, Osborne DW, Chow DSL.2008. Cremophor-free intravenous microemulsions for paclitaxel: I:Formulation, cytotoxicity and hemolysis. Int J Pharm,349(1-2):108～116.
Obmi s ka-Domoradzka B, S Witala M, Debowy J, Garbuliński T.1995. Effects of levamisole, DTC andlow-dose lechlorethamine on humoral response of SRBC-immunized rabbits exposed to cold stress.Zentralbl Veterinarmed B,42(1-10):12～18.
O'Hagan DT, Valiante NM.2003. Recent advances in the discovery and delivery of vaccine adjuvants. NatRev Drug Discov.2(9):727～735.
Okur Nü, Apayd n, Yava o lu NüK, Yava o lu A, Karasulu HY.2011. Evaluation of skin permeationand anti-inflammatory and analgesic effects of new naproxen microemulsion formulations. Int JPharm,416(1):136～144.
Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K.1991. Properties of the novel proinflammatorysupergene "intercrine" cytokine family. Annu Rev Immunol,9:617～948.
Park D, Bae DK, Jeon JH, Lee J, Oh N, Yang G, Yang YH, Kim TK, Song J, Lee SH, Song BS, Jeon TH,Kang SJ, Joo SS, Kim SU, Kim YB.2011. Immunopotentiation and antitumor effects of a ginsenosideRg3-fortified red ginseng preparation in mice bearing H460lung cancer cells. Environ ToxicolPharmacol,31(3):397～405.
Panigraphy B, Grumbles LC, Millar M, Naqvi SA, Hall CF.1979. Antibiotic-induced immunosuppressionand levamisole-induced immunopotentiation in turkeys. Avian Dis,23(2):401～408.
Pearse MJ, Drane D.2004. ISCOMATRIX adjuvant: a potent inducer of humoral and cellularimmune responses. Vaccine,22(19):2391～2395.
Pekmezci D, Cakiroglu D.2009. Investigation of immunmodulatory effects of levamisole and vitamin E onimmunity and some blood parameters in newborn Jersey calves. Vet Res Commun,33(7):711～721.
Phan TT, Attaphong C, Sabatini DA.2011. Effect of extended surfactant structure on interfacial tension andmicroemulsion formation with triglycerides. Journal of the American Oil Chemists' Society,88(8):1223～1228.
Plevyak M, Hanna N, Mayer S, Murphy S, Pinar H, Fast L, Ekerfelt C, Ernerudh J, Berg G, Matthiesen L,Sharma S.2002. Deficiency of decidual IL-10in first trimester missed abortion: a lack of correlationwith the decidual immune cell profile. Am J Reprod Immunol,47(4):242～250.
Prow TW, Grice JE, Lin LL, Faye R, Butler Ma, Becker W, Wurm EMT, Yoong C, Robertson TA, Soyer HP,Roberts MS.2011. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev,63(6):470～491.
Pu Z, Zhang PJ, Gao YG, Hao JX, Wang YX, Li R, Yang H, Li X, Li P, Zhou DW, Zhang LX.2011. Theevaluation of contents of nine ginsenoside monomers in ginseng hairy roots by high performanceliquid chromatography (HPLC). Journal of Medicinal Plants Research,5(23):5513～5516.
Qi LW，Wang CZ，Yuan CS．2011. Isolation and analysis of ginseng: advances and challenges．Nat ProdRep,28(3):467～495.
Qu DF, Yu HJ, Liu Z, Zhang DF, Zhou QJ, Zhang HL, Du AF.2011. Ginsenoside Rg1enhances immuneresponse induced by recombinant Toxoplasma gondii SAG1antigen. Vet Parasitol,179(1-3):28～34.
Qureshi ZI, Lodhi LA, Jamil H, Nawaz M.2000. Effect of levamisole hydrochloride on serum and colostralantibody titres against foot and mouth disease virus in vaccinated buffaloes (Bubalus bubalis).Veterinarski Arhiv,70(2):59~66.
Reyero C, St ckl W, Thalhammer JG.1979. Stimulation of the antibody response to sheep red blood cells inpiglets and young pigs by levamisole. Br Vet J,135(1):17～24.
Rivera E, Hu S, Concha C.2003a. Ginseng and aluminium hydroxide act synergistically as vaccineadjuvants. Vaccine,21(11-12):1149～1157.
Rivera E, Daggfeldt A, Hu S.2003b. Ginseng extract in aluminium hydroxide adjuvanted vaccinesimproves the antibody response of pigs to porcine parvovirus and Erysipelothrix rhusiopathiae. VetImmun Immunopathol,91(1):19～27.
Rivera E, Ekholm Pettersson F, Ingan s M, Paulie S, Gr nvik KO.2005. The Rb1fraction of ginsengelicits a balanced Th1and Th2immune response. Vaccine,23(46-47):5411～5419.
Rothenberg EV, Diamond RA, Pepper KA, Yang JA.1990. IL-2gene inducibility in T cells before T cellreceptor expression. Changes in signaling pathways and gene expression requirements duringintrathymic maturation. J Immunol,144(5):1614～1624.
Sadigh-Eteghad S, Khayat-Nuri H, Abadi N, Ghavami S, Golabi M, Shanebandi D.2011. Synergetic effectsof oral administration of levamisole and Echinacea purpurea on immune response in Wistar rat.Research in Veterinary Science,91(1):82～85.
Saini SS, Sharma JK, Joshi VB, Kwarta MS.1991. Effect of levamisole on humoral immune response ofcow-calves vaccinated with Brucella abortus strain19vaccine. Indian J Ari Res,25:69～72.
Sampson D, Lui A.1976. The effect of levamisole on cell-mediated immunity and suppressor cell function.Cancer Res,36(3):952～955.
Sanadgol H, Khoshnoodi M, Mashhadi MA, Forghani MS.2011. Effect of adding levamisole onseroconversion response to hepatitis B virus vaccination in hemodialysis patients: a single-centerexperience. Iran J Kidney,5(5):338～341.
Sanz MJ, Weg VB, Bolanowski MA, Nourshargh S.1995. IL-1is a potent inducer of eosinophilaccumulation in rat skin. Inhibition of response by a platelet-activating factor antagonist and ananti-human IL-8antibody. J Immunol,154(3):1364～1373.
Seyed-Moayed Alavian MD, Seyed-Vahid Tabatabaei MD.2010. Effects of oral levamisole as an adjuvantto hepatitis B vaccine in adults with end-stage renal disease: A meta-analysis of controlled clinicaltrials. Clinical Therapeutics,32(1):1～10.
Shakeel F, Ramadan W.2010. Transdermal delivery of anticancer drug caffeine from water-in-oilnanoemulsions. Colloids Surf B Biointerfaces,75(1):356～362.
Sharma LK, Jagadish S, Mulbagal AN.1990. Effects of haemorrhagic septicaemia vaccination andlevamisole administration on the humoral response in cross-bred calves. J Vet Pharmacol Ther,13(1):23～28.
Sharma LK, Jagadish S, Mulbagal AN.1993. Effect of levamisole on delayed-type hypersensitivity incrossed calves. Indian Veterinary Journal,70(8):699～701.
Shen Q, Li X, Li WJ, Zhao XY.2011. Enhanced intestinal absorption of daidzein by borneol/mentholeutectic mixture and microemulsion. AAPS PharmSciTech,12(4):1044～1049.
Shibata H, Kimura-Takagi I, Nagaoka M, Hashimoto S, Aiyama R, Iha M, Ueyama S, Yokokura T.2000.Properties of fucoidan from Cladosiphon okamuranus tokida in gastric mucosal protection. Biofactors,11(4):235～245.
Shishu, Kamalpreet, Maheshwari M.2012. Development and evaluation of novel microemulsion based oralformulations of5-fluorouracil using non-everted rat intestine sac model. Drug Dev Ind Pharm,38(3):294～300.
Singh LDK, Rao AT.1988. Effect of levamisole and prednisolone on chicken infected with infectionsbursal disease virus. India J Ani Sci,58(5):589～593.
Sintov AC, Levy HV, Botner S.2010. Systemic delivery of insulin via the nasal route using a newmicroemulsion system: In vitro and in vivo studies. J Control Release,148(2):168～176.
Siwicki AK, Cossarini-Dunier M.1990. Effect of levamisole on the lymphocyte and macrophage activity incarp (Cyprinus carpio). Ann Rech Vet,21(2):95～100.
Srinivasa Rao TV, Mishra, SC, Jaiswal TN,1994. Effect of levamisole on complement levels in chickensvaccinated and challenge infected with infectious bronchitis virus. Indian Veterinary Journal,71,8～11.
Song Z, Wu H, Mathee K, H iby N, Kharazmi A.2002. Gerimax ginseng regulates both humoral andcellular immunity during chronic Pseudomonas aeruginosa lung infection. J Altern Complement Med,8(4):459～466.
Song Z, Moser C, Wu H, Faber V, Kharazmi A, H iby N.2003. Cytokine modulating effect of ginsengtreatment in a mouse model of Pseudomonas aeruginosa lung infection. J Cyst Fibros,2(3):112～119.
Song Z, Moser C, Wu H, Larsen MW, Johansen HK, Faber V, Kharazmi A, H iby N.2005. Ginsengmodulates the immune response via its effect on cytokine production--secondary publication. UgeskrLaeger,167(33):3054～3056.
Song XM, Bao SJ, Wu LH, Hu SH.2009a. Ginseng stem-leaf saponins (GSLS) and mineral oil actsynergistically to enhance the immune responses to vaccination against foot-and-mouth disease inmice. Vaccine,27(1):51～55.
Song XM, Zang LM, Hu SH.2009b. Amplified immune response by ginsenoside-based nanoparticles(ginsomes). Vaccine,27(17):2306～2311.
Song XM, Chen J, Sakwiwatkul K, Li RL, Hu SH.2010. Enhancement of immune responses to influenzavaccine (H3N2) by ginsenoside Re. Int Immunopharmacol,10(3):351～356.
Soppi E, Lassila O, Viljanen MK, Lehtonen OP, Eskola J.1979. In vivo effect of levamisole on cellular andhumoral immunity in normal chickens. Clin Exp Immunol,38(3):609～614.
Sun HX, Chen Y, Ye Y.2006. Ginsenoside Re and notoginsenoside R1: Immunologic adjuvants with lowhaemolytic effect. Chem Biodivers,3(7):718～726.
Sun JH, Song XM, Hu SH.2008. Ginsenoside Rg1and aluminum hydroxide synergistically promoteimmune responses to ovalbumin in BALB/c mice. Clin Vaccine Immunol,15(2):303～307.
Sun YX, Tong HB, Li MQ, Li YJ, Guan SW, Liu JC.2008. Immunological adjuvant effect of Japaneseginseng saponins (JGS) on specific antibody and cellular response to ovalbumin and its haemolyticactivities. Vaccine,26(47):5911～5917.
Sun S, Qi LW, Du GJ, Mehendale SR, Wang CZ, Yuan CS.2011. Red notoginseng: higher ginsenosidecontent and stronger anticancer potential than Asian and American ginseng. Food Chem,125(4):1299～1305.
Szeto C, Gillespie KM, Mathieson PW.2000. Levamisole induces interleukin-18and shifts type1/type2cytokine balance. Immunology,100(2):217～224.
Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA.1990. Induction of CD8+cytotoxic T cells by immunization with purified HIV-1envelope protein in ISCOMs. Nature,344:873～875.
Tian ZG, Yang GZ.1993. Promoting effect of panaxatriol ginsenoside on gene expression of humaninterleukin-1. Acta Pharmacol Sin,14(3):159～161.
Tsai YH, Lee KF, Huang YB, Huang CT, Wu PC.2010. In vitro permeation and in vivo whitening effect oftopical hesperetin microemulsion delivery system. Int J Pharm,388(1-2):257～262.
Tung NH, Yang SY, Kim JH, Song GY, Kim YH.2010. Dammarane-type saponins from the black ginseng.Bull. Korean Chem. Soc,31(11):3423～3426.
Ustünda Okur N, Apayd n S, Karabay Yava o lu Nü, Yava o lu A, Karasulu HY.2011. Evaluation ofskin permeation and anti-inflammatory and analgesic effects of new naproxen microemulsionformulations. Int J Pharm,416(1):136～144.
Vander Maaten MJ, Schmerr MJ, Miller JM, Sacks JM.1983. Levamisole does not affect the virologicaland serological responses of bovine leukemia virus-infected cattle and sheep. Can J Comp Med,47(4):474～479.
Verhagen H, DeCree J, DeCock W, Verbruggen F.1973. Levamisole and the immune response. N Engl JMed,289:1148～1149.
Vyas TK, Babbar AK, Sharma RK, Singh S, Misra A.2006. Intranasal mucoadhesive microemulsions ofclonazepam: preliminary studies on brain targeting. J Pharm Sci,95(3):570～580.
Vyas TK, Shahiwala A, Amiji MM.2008. Improved oral bioavailability and brain transport of saquinavirupon administration in novel nanoemulsion formulations. Int J Pharm,347(1-2):93～101.
Wang Y, Wang BX, Liu TH, Minami M, Nagata T, Kejima T.2000. Metabolism of ginsenoside Rg_1byintestinal bacteria Ⅱ. Immunological activity of ginsenoside Rg-1and Rh-1. Acta Pharmacol Sin,21(9):792～796.
Wang KX, Zhang LH, Peng JL, Liang Y, Wang XF, Zhi H, Wang XX, Geng HX.2005. Effect of linimentlevamisole on cellular immune functions of patients with chronic hepatitis B. World J Gastroenterol,11(45):7208～7210.
Wang X, Jin H, Du X, Cai C, Yu Y, Zhao G, Su B, Huang S, Hu Y, Luo D, She R, Luo X, Zeng X, Yi X,Wang B.2008. The protective efficacy against Schistosoma japonicum infection by immunizationwith DNA vaccine and levamisole as adjuvant in mice. Vaccine,26(15):1832～1845.
Wu JY, Gardner BH, Murphy CI, Seals JR, Kensil CR, Recchia J, Beltz GA, Newman GW, Newman MJ.1992. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1vaccine. J Immunol,148(5):1519～1525.
Xu H, Dilulio NA, Fairchild RL.1996. T cell populations primed by hapten sensitization in contactsecsitiviry are distinguished by polarized patterns of cytokine production: interferongamma-producing (Tc1) effectors CD8+T cell and interleukin (Ⅱ)4/-10-producing (Th2) negativeregulatory CD4+T cell. J Exp Med,183(3):1001～1012.
Xu L, Pan J, Chen Q, Yu Q, Chen H, Xu H, Qiu Y, Yang X.2008. In vivo evaluation of the safety oftriptolide-loaded hydrogel-thickened microemulsion. Food Chem Toxicol,46(12):3792～3799.
Yang ZG, Ye YP, Sun HX.2007a. Immunological adjuvant effect of ginsenoside Rh4from the roots ofPanax notoginseng on specific antibody and cellular response to ovalbumin in mice. Chem Biodivers,4(2):232～240.
Yang ZG, Chen AQ, Sun HX, Ye YP, Fang WH.2007b. Ginsenoside Rd elicits Th1and Th2immuneresponses to ovalbumin in mice. Vaccine,25(1-2):161～169.
Yen MH, Lin CC and Yen CM.1995. The immunomodulatory effect of saikosaponin derivatives and theroot extract of Bupleurum kaoi in mice. PhytotherRes,9(5):351～358.
Yin J, Jin H, Kang Y, Xiao C, Zhao L, Li X, Ding Z, Yang F, Zhu Q, Wang B.2006. Efficacy of modifiedlevamisole adjuvant on inactivated virus vaccine. Viral Immunol,19(3):525～535.
Yu JL, Dou DQ, Chen XH, Yang HZ, Guo N, Cheng GF.2004. Immunoenhancing activity ofprotopanaxatriol-type ginsenoside-F3in murine spleen cells. Acta Pharmacol Sin,25(12):1671～1676.
Yu JL, Dou DQ, Chen XH, Yang HZ, Guo N, Cheng GF.2005. Protopanaxatriol-type ginsenosidesdifferentially modulate type1and type2cytokines production from murine splenocytes. Planta Med,71(3):202～207.
Zhang QZ, Jiang XG, Jiang WM, Lu W, Su LN, Shi ZQ.2004. Preparation of nimodipine-loadedmicroemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int JPharm,275(1-2):85～96.
Zhang H, Cui YN, Zhu SM, Feng FQ, Zheng XD.2010. Characterization and antimicrobial activity of apharmaceutical microemulsion. Int J Pharm,395(1-2):154～160.
Zhang J, Michniak-Kohn B.2011. Investigation of microemulsion microstructures and their relationship totransdermal permeation of model drugs: ketoprofen, lidocaine, and caffeine. Int J Pharm,421(1):34～44.
Zhou ZX, Qu Y, Dou DQ, Liu FY, Huo YS, Jiao FB.2011. The ginsenoside profile of ginseng cultivatedunder mountainous forest. Journal of Medicinal Plants Research,5(3):410～419.
Zhu WW, Yu AH, Wang WH, Dong RQ, Wu J, Zhai GX.2008. Formulation design of microemulsion fordermal delivery of penciclovir. Int J Pharm,360(1-2):184～190.
Zhu J, Zhang XY, Gao F, Chen M, Huang SQ.2011. Preparation and properties of alkoxysilane/acrylatecopolymer microemulsion. Journal of Polymer Research,18(6):1991～1997.
毕殿洲.1999.药剂学.北京:人民卫生出版社:101.
蔡伟惠,陈小平,金方.2011.微乳型丙泊酚纳米注射液的制备与评价.中国新药杂志,20(13):1170～1173.
曹丽,顾学文,张天一,汪骅.2011.人参皂甙对小鼠腹腔巨噬细胞活性的影响及其作用机制初步探讨.中国免疫学杂志,27(5):423～426.
常雅萍,杨贵贞.1992.几种中药提取物诱生人干扰素.中国实验临床免疫学杂志,4(6):37～40.
常雅萍,吴雅珍,李平亚,宋玉珍,明月,刘金平,霍德胜.2000. G-Rg治疗单疱病毒性角膜炎实验观察.白求恩医科大学学报,26(2):134～136.
陈明侠,徐华丽,于小风,曲绍春,睢大员,李绪文,金永日.2007.20(S)-原人参二醇的抗肿瘤及免疫调节作用研究.中国药师,10(12):1165～1168.
陈曜,陈春山.2010.人参皂甙小分子的生物学作用.临床和实验医学杂志,9(21):1658～1662.
陈木洲,刘延辉,黄姬,江丹娜.2011.酸碱度对人参皂苷提取率及其稳定性影响分析.中国实用医药,6(20):146～147.
程晓耕,赵雪俭,迟宝琦,曹杰,张淑洁,王晓宇,王成,朱燕.2004. IFN和PDS合剂体内抗流感病毒的作用.微生物学杂志,24(5):64～65.
褚秀玲,苏建青,韦旭斌.2010a.细胞病变观察法检测人参皂苷及其衍生物抗马立克氏病病毒的作用.中国畜牧兽医,37(3):179～183.
褚秀玲,苏建青,韦旭斌.2010b.人参皂苷及其衍生物抗马立克氏病毒的作用.畜牧与兽医,42(3):67～71.
褚秀玲,苏建青,韦旭斌.2010c.人参皂苷Rg3体内抗马立克氏病毒的作用.湖北农业科学,49(1):143～146.
储岳峰,李祥瑞,颜新敏,胡元亮.2005.九种中药成分对体外培养小鼠淋巴细胞功能的影响.中国兽医科技,35(11):908～911.
但汉雄,刘翠霞,江南.2003.人参二醇甙对实验动物的免疫促进作用.湖北中医学院学报,5(1):36～38.
傅红燕,任晓斌.1998.血塞通注射液pH值对其主要皂苷成分的影响.广东药学院学报,14(4):284～286.
葛迎春,李晨燕,任慧君,马天舒,刘平.2002.人参皂甙Rh2注射液对荷肝癌(H22)小鼠免疫功能的影响.特产研究,24(3):4～7.
顾立学,燕春义,罗俊生.2007.人参皂苷对小鼠G422胶质瘤免疫功能的影响.辽宁中医杂志,34(4):523～524.
管孝鞠,吴玉章.2001.人用疫苗佐剂研究中存在的问题.中国生化药物杂志,22(4):210～212.
郭志廷,韦旭斌,梁剑平,单提新.2007.人参总皂苷及其衍生物对小鼠淋巴细胞和NK细胞免疫活性的影响.中国兽医学报,27(5):715～718.
韩大良,黄畅,郭少三,周希瑜.2008.人参皂苷Rb1对体外条件下小鼠骨髓间充质干细胞和粒-巨噬系祖细胞增殖的影响.中华中医药学刊,26(6):1192～1193.
胡元亮,刘家国,陈玉库,张宝康,孙祥峰,王效田.2003.中药成分对传染性法氏囊感染细胞的影响.畜牧与兽医,35(12):8～10.
呼显生,马玉敏,马明颖,吴斌,姜成.2005.人参皂甙Rb1对禽流感疫苗的免疫佐剂作用.河南农业科学,(12):79～81.
黄辉,李义,郝向举.2008.左旋咪唑对罗氏沼虾免疫功能及抗病力的影响.淡水渔业,38(4):36～39.
黄琼,杨杏芬,黄俊明,李志,杨明杰,黄建康.2004. CD+69/CD+3比值和左旋咪唑对照在评价保健食品免疫调节作用中的应用研究.中国卫生杂志,14(1):42～44.
贾宁,王汉,郑晶.2011.复方党参提取物对环磷酰胺处理小鼠免疫功能的调节作用.中国实验方剂学杂志,17(17):206～209.
姜建华,张学进,王育丽.2005.人参皂苷对60Co照射小鼠不良反应的影响.浙江中西医结合杂志,15(11):682～683.
姜东平.2008.玉屏风口服液对鸡新城疫和法氏囊病疫苗免疫效果的影响.畜禽业,232(8):50～52.
江兴林,蒋乐龙,胡祥上,王玉爱,田小英,邓伟峰,房华,刘辉.2006.中药白芍对小鼠体液免疫功能影响的探讨.怀化医专学报,5(2):54～55.
蒋蕊,考书娟,徐小娟,徐德武.2011.槲皮素对免疫低下小鼠体液免疫功能的影响.青岛农业大学学报（自然科学版）,28(2):118～120.
焦成美,刘洪卓,金玲宇,张宇,李三鸣.2008.鼻腔给药地西泮微乳的制备及性质考察.中国药剂学杂志,6(4):156～161.
雷萍,关洪全,王昊,韩晓伟,侯殿东,陈殿学.2011.不同产地人参水煎剂对免疫抑制小鼠细胞免疫功能的影响,中国实验方剂学杂志,17(8):218～220.
李春梅,黄永坚.2002.左旋咪唑对鲫鱼血液吞噬细胞活性的影响,黄冈职业技术学院学报,4(3):26～28.
李桂华,乔彦良,魏爱红,遇欣,曹福敏,孙爱玉.2002.左旋咪唑对鸡离体外周血淋巴细胞的作用.山东家禽,(5):14～17.
李静波,张鸿源,马兴原.1992.人参茎叶皂甙与Rb1等单体对病毒复制的影响.白求恩医科大学学报,18(1):24～26.
李静波,王秀清,孙非.1993.人参茎叶皂甙对单纯疱疹病毒感染细胞的保护作用及与cAMP的关系.吉林中医药,1993,(1):41～42.
李凌夫,王曾力,张燕,王雅贤,杨宝华,贾宽,张德山.1996a.人参皂苷-Rc对正常成人外周血NK及LAK细胞活性影响的实验研究.中医药信息,(2):52~54.
李凌夫,王冬,张燕等,王雅贤,杨宝华,贾宽,张德山.1996b.人参皂苷-Re对正常成人外周血LAK和NK细胞活性影响的实验研究.中医药信息,(3):54~55.
李平亚,郝秀华,赵春芳,常雅萍,王博藯,吴浩.2001.人参皂甙-Rg3、-Rb3抗病毒作用的研究.中国老年学杂志,21(5):215～216.
李卫平,陈敏珠.1998.人参皂苷的免疫调节作用．安徽医科大学学报,33(5):348～350.
李晓林,王静凤,田守生,傅佳,赵芹,李冰,薛长湖.2010.海参和鱼翅的营养成分以及对免疫功能调节作用的比较.中国海洋大学学报,41(1-2):65～70.
李玉赜,张连学,姚允怡,齐宪辉,郜玉钢.2011.人参皂苷抗梅花鹿源BVDV研究.安徽农业科学,39(23):14036～14044.
李兆明,姬涛,侯林,田景振.2009.比色法测定保健酒中人参总皂苷含量.吉林中医药,29(5):425～426.
黎阳,张铁军,刘素香,陈常青.2009.人参化学成分和药理研究进展.中草药,40(1):164～166.
梁华平,王正国,田丰群,耽波，陈荣德.1995a.黄芪多糖、人参茎叶皂甙对创伤小鼠血浆及免疫细胞内cAMP、cGMP的影响.中国病理生理杂志,11(6):595～599.
梁华平,王正国,田丰群,耿波,陈荣德.1995b.烧伤后白介素与白介素受体基因表达的变化及人参茎叶皂甙的调节作用.第三军医大学学报,17(5):103～106.
梁华平,王正国,耿波,天风群,罗艳,徐祥.1996.黄芪多糖及人参茎叶皂甙对创伤小鼠免疫器官影响.中医研究,9(2):15～17.
刘安刚,李引乾,孙娇,孙薇薇,赵建乐,俞亚玲,王成龙,姬双双.2011.氟苯尼考纳米乳的制备及品质评价.西北农业学报,20(5):44～49.
刘芬娣,李德全.2010.人参配伍五灵脂人参总皂苷的含量变化规律研究.首都医药,(22):40～41.
刘红樱,葛均波,马晓娟,史大卓.2011.人参皂苷Rb1对氧化型低密度脂蛋白诱导的人单核细胞源树突状细胞免疫成熟的影响.中国中西医结合杂志,31(3):350～354.
刘靖华,陈惠孙,胡德耀,刘良明.2000.人参皂甙对创伤失血性休克免疫功能的调节作用.第三军医大学学报,22(4):324～327.
刘丽芳,张阳德.2010.中药纳米乳研究进展,中医药导报,16(8):112～115.
刘忞,张均田.1996.人参皂甙Rg1对老年大鼠免疫调节作用的机制分析.药学学报,31(2):95～100.
刘素梅,李华岑,韩立,徐银凤,臧合英,张要京,王军红.2010.万乳康中盐酸左旋咪唑含量测定方法的研究.中国兽药杂志,44(2):26～28.
刘伟宏,龚守良,李新民,刘树铮.1994.人参三醇组甙对雄性大鼠免疫器官的辐射防护作用.白求恩医科大学学报,20(1):32～34.
刘轩,魏育林,李波,李亚俊,金恩源,王学静．2001.人参皂苷对脂多糖诱导小鼠肺泡巨噬细胞分泌肿瘤坏死因子的作用及机制探讨．中日友好医院学报，15(2):83～86.
陆振达,耿惠珍.1995.稳定盐酸左旋咪唑注射液PH的试验.现代应用药学,12(6):3～4.
骆艳秋,尹柏双,徐文勇,姜成.2008.人参叶皂甙对鸡免疫功能调节的研究.安徽农业科学,36(1):202～204.
吕梦捷,曾耀英,宋兵.2011.人参皂甙Rb1对小鼠腹腔巨噬细胞体外吞噬及细胞因子和NO分泌的影响.细胞与分子免疫学杂志,27(3):242～245.
毛平,马骏,陈艳艳,虞桂珍,谭梦晖.2006.不同药性补气中药对小鼠脾淋巴细胞增殖及细胞因子分泌的影响.上海中医药大学学报,20(3):49～51.
梅少林,袁红艳,曹湘博,常雅萍,李平亚,刘金萍.2006.人参皂苷Rg3体外抗HSV-1活性与免疫调节效应.吉林大学学报（医学版），32(6):1019～1022.
梅少林,袁红艳,曹湘博,常雅萍,李平亚,刘金萍.2007.人参皂苷Rg3对HSE模型鼠的治疗作用及免疫调节效应.吉林大学学报（医学版），33(1):119～122.
聂奎.1989.左旋咪唑的免疫学药理作用及其应用.国外兽医学-畜禽疾病,(4):1～5.
牛华星,李淑花,张传津.2009.盐酸左旋咪唑-维生素E可溶性粉对鸡免疫功能增强作用研究.山东畜牧兽医,30(8):13～15.
潘维华,刘晓颖,王英平,刘继永.2011.人参皂苷对小鼠脾淋巴细胞和腹腔巨噬细胞免疫活性的影响.特产研究,33(1):16～19.
乔彦良,杨汉春,郭玉璞,盛英霞,马贤本,付兴伦.2000.左旋咪唑对鸡细胞免疫和体液免疫功能的作用.畜牧与兽医,32(2):1～4.
乔彦良,初晓翠,孙爱玉,盛英霞,张妍,贺营,韩治桃,杨汉春,郭玉璞.2001.左旋咪唑对地塞米松预处理鸡免疫功能的影响.兽药与饲料添加剂,6(4):3～5.
曲婷婷,金岩,柳越冬,井欢,刘树权,关洪全,李建春.2006.人参皂苷Rb1、Rg1与5-氟脲嘧啶对荷瘤小鼠免疫功能的影响.中医研究,19(5):16～18.
任杰红,陈林芳,张路晗,程睿.2002.人参皂苷Rg1的免疫促进作用.中药新药与临床药理,13(2):92～93.
苏建青,褚秀玲,韦旭斌.2010.人参皂苷及其衍生物体内抗马立克氏病毒的间接免疫荧光观察与PCR检测.中国兽医学报,30(4):485～488.
田志刚,杨贵贞.1991.人参三醇皂甙促进人淋巴结细胞IFN-γ基因表达.上海免疫学杂志, l1(2):82～84.
田志刚,刘杰,孙汭,李柏青,张捷,张建华.1993.人参三醇型皂甙对IL-6基因的促转录效应.中国药理学通报,9(5):371～372.
肖啸,杨继生,张静,肖焰.2008a.左旋咪唑对仔猪免疫指标的影响.甘肃畜牧兽医,(4):2～4.
肖啸,杨林富,代飞燕,赵辉斌.2008b.左旋咪唑对犬免疫指标的影响.山东畜牧兽医,29(10):6～7.
王斌,李杰芬,胡岳山.2003.人参皂甙对小鼠脾脏树突状细胞增殖的影响.上海免疫学杂志,23(6):381～382.
王德云,胡元亮,孔祥峰,孙峻岭,张宝康,刘家国,夏明龙.2005.中药成分对培养的鸡脾脏淋巴细胞增殖的影响.畜牧兽医学报,36(11):1210～1214.
王鹤尧,郑文婕.2006.左旋咪唑腔给药改变小鼠变应性鼻炎黏膜局部的Thl/Th2免疫应答.中国新药杂志,15(17):1446～1450.
王静凤,李晓林,滕来宾,薛勇,傅佳,赵芹,薛长湖.2011.海参虫草复剂对免疫功能低下小鼠的免疫调节作用.卫生研究,40(2):215～218.
王书全，王晓玉.2010.左旋咪唑对鸡新城疫LaSota疫苗免疫效果的影响.中国家禽,32(19):31～33.
王庭富,孟正木.1999.人参皂甙Rg3对免疫功能的影响．中国药科大学学报,30(2):133～135.
王晓黎,蒋雪涛,李干佐,牟建海.2001.非离子型表面活性剂微乳的基础研究.解放军药学学报,6(17):197～300.
王新卫,杨永珍,王艳.2008.左旋咪唑对新城疫灭活疫苗抗体滴度的影响.中国农学通报24(12):1～3.
王新卫,邹正耀,杨霞,张红英.2009.左旋咪唑影响流感灭活疫苗（H9N2）抗体滴度.中国农学通报,25(20):38～41.
王毅,郝钰,邱全瑛,黄启福.2007.人参皂苷Rg1与Rh1对树突状细胞表达HLA-DR、CD25、CD44、CD54、CD11c及E-selectin的影响.中医中药与免疫,23(1):46～49.
危建安,程志安,温建炫,戴韵峰,莫嘉强.2011.人参多糖与人参皂苷诱导大鼠骨髓间充质干细胞造血细胞因子表达的作用比较.中国中西医结合杂志,31(3):372～375.
魏永俊,潘玉善,苑丽,刘建华,陈玉霞,胡功政,王立业,骈永亮.2010.妥曲珠利纳米乳的研制及其初步质量评价.江西农业学报,22(3):146～149.
吴东东,刘琪.2010.人参皂苷Rg3对环磷酰胺的增效作用.医药导报,29(07):850～853.
吴章怀,秦大莲,岳永花,邓莎,周淼,刘剑.2009.脑舒胶囊对免疫低下小鼠免疫功能的调节作用.时珍国医国药,20(9):2336～2337.
向枭,向勇,冯君,胡美蓉.2002.甲壳素和左旋咪唑对罗非鱼的对比生长试验.饲料工业,23(11):43～45.
谢明权,宋长绪,黄忠.2000.5种免疫增强剂对猪PBMC增殖反应的影响.中国兽医学报,20(5):485～486.
许丹妮,李健,马玉芳,黄一帆.2011.金线莲多糖对免疫抑制小鼠脾淋巴细胞增殖及免疫器官的影响.中兽医医药杂志,13(3):15～17.
许国焕,余进峰,唐峻峰,赵新安,郑莲春.2001.几种促生长剂对中华鳖养殖效果的研究.水利渔业,21(1):33～34.
严铭铭,王旭,钟英杰,李龙云,曲晓波,赵大庆.2006.人参皂苷Rg2注射液制备工艺的研究.中草药,37(5):697～700.
杨帆,陆益,李艳,梁宁生,蒙子卿.2004.复方华蟾胶囊对小鼠免疫功能的影响.中国医院药学杂志,24(8):451～452.
杨帆,席伟,谢裕安,黎远冬,罗小玲,匡志鹏,吴继宁,李蕾.2011.蛤蚧肽对小鼠免疫功能的调节作用.广西医科大学学报,28(3):342～344.
杨贵贞,鲍涛,富宁,耿排力.1983.人参皂甙对体内外免疫调整作用的初步研究.白求恩医科大学学报,9(3):1～7.
张才军，郭民，柳波，后文俊，王玲.2009.人参皂苷Rh1对免疫功能降低小鼠的免疫调节作用研究.昆明医学院学报,30(11):51～54.
张春晶,顾立刚,牛旭艳,王甫,彭桂英.2009.人参皂苷Rg1和Rb1对流感病毒感染细胞的影响及其机制研究.中华微生物学和免疫学杂志,29(10):894～900.
张发亮,叶勇.2008.0.5%伊维菌素微乳剂的研制.安徽农业科学.36(1):231～233.
张华,薛家宾,黄克和,陈兴祥,徐为中.2004.左旋咪唑对正常和受抑制兔体外淋巴细胞转化的影响.江苏农业科学,(5):86～88.
张兰兰,闫明,刘晓东,霍仕霞.2009.驱白巴布期片对小鼠免疫功能的影响.时珍国医国药,20(8):1893～1895.
张勤,叶再元,杜卫东.2003.人参皂甙对腹腔感染大鼠血清白蛋白及白介素-6影响的实验研究.浙江中医学院学报,27(4):66～67.
张日俊,黄燕,佟建民,萨仁娜.1999.饲用左旋咪唑对肉仔鸡免疫功能调节作用的研究.中国畜牧杂志,35(5):5～8.
张锐,徐华丽,于小风,曲绍春,陈明侠,睢大员.2009.20(S)-原人参二醇对荷瘤裸鼠化疗的增效减毒作用.吉林大学学报（医学版）,35(2):195～200.
张善玉,朴惠顺,申英爱.2005.黄芪多糖与人参总皂苷联用的免疫调节作用初步研究.中药房,(16)21:1620～1622.
张松莲.2007.仙人掌多糖免疫调节作用的研究.[硕士论文].湖南：湖南农业大学.
张晓文,宋清,徐志伟.2010.人参茎叶总皂苷对心理应激荷瘤小鼠肿瘤生长及化疗效果的影响.现代食品科技,26(4):348～350.
张霄翔,王艳苹,王玉凤,陈少兵.2009a.瓜蒌皮对环磷酰胺致免疫功能低下小鼠免疫功能的影响.中国药房,20(9):648～650.
张霄翔,王艳苹,王玉凤,陈少兵.2009b.甘寒归肝肾经中药药性研究（Ⅰ）—对免疫功能低下小鼠免疫功能的影响.中华中医药杂志,24(2):240～242.
张瑛,孟建国,王成,申圣丹,王盛民.2010.人参不同制品对小鼠淋巴细胞增殖免疫功能的影响.时珍国医国药,22(4):867～868.
郑晓波,张世华.2000.左旋咪唑对试验兔创伤愈合的影响研究.甘肃畜牧兽医,30(2):20～22.
周才琼,张雨.2008.印度人参根提取物的免疫调节作用.食品科学,29(7):412～415.
周东波,胡成平,梁硕,杨红忠.2007.人参单体皂甙Rh2对非小细胞肺癌患者肺泡巨噬细胞免疫活性的影响.中南大学学报（医学版）,32(5):868～872.
周娅红.2010.人参总皂苷对免疫低下小鼠免疫功能的影响.中国中医急症,19(9):1559～1561.
周英武,彭桂英,顾立刚,殷胜骏.2010.利用生物芯片技术检测人参皂苷Rg1对小鼠树突状细胞功能调控相关基因表达的影响.中国免疫学杂志,26(12):1086～1090.
Akaza H, Yokoyama H, Umeda T, Niijima T.1979. Restoration by levamisole of E-rosette formation andits abrogation by autochthonous serum from patients with bladder cancer. Cancer,43(1):97～100.
Ammar HO, Salama HA, M Ghorab, Mahmoud AA.2009. Nanoemulsion as a potential ophthalmicdelivery system for dorzolamide hydrochloride. AAPS PharmSciTech,10(3):808～819.
Bali V, Ali M, Ali J.2010. Study of surfactant combinations and development of a novel nanoemulsion forminimising variations in bioavailability of ezetimibe. Colloids Surf B Biointerfaces,76(2):410～420.
Batungbacal MR.1993. The effect of levamisole hydrochloride on the immune response of chicens toinfections coryza vaccine. Philippine Journal of veterinary medicine,30(1):27～31.
Bevilaqua MP.1993. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol.11:767～804.
Bonagura VR, Hatam L, DeVoti J, Zeng F, Steinberg BM.1999. Recurrent respiratory papillomatosis:altered CD8(+) T-cell subsets and T(H)1/T(H)2cytokine imbalance. Clin Immunol,93(3):302～311.
Bo i F, Banovi F, uran J, Crni AP.2011. Adjuvant activity of levamisole for experimental F18ac(+)Escherichia coli oral vaccine against porcine post-weaning colibacillosis. Veterinarski Arhiv,81(2):199～209.
Cabaj W, Stankiewicz M, Jonas WE, Moore LG.1995. Levamisole and its influence on the immuneresponse of lambs. Vet Res Commun,19(1):17～26.
Campbell, JB.1995. Saponins. In: Stewart-Tull DES. The theory and practical application of adjuvants.New York: John Wiley&Sons Ltd.:95～127.
Cevc G., Vierl U.2010. Nanotechnology and the transdermal route: A state of the art review and criticalappraisal. J Control Release,141(3):277～299.
Chai JL, Wu YT, Li XQ, Yang B, Chen LS, Shang SC, Lu JJ.2011. Effect of alkane/water ratios on thephase behavior and the solubilization of microemulsion systems containinghexadecyltrimethylammonium bromide. J. Chem. Eng. Data,56(1):48～52.
Chan SH, Simons MJ.1975. Levamisole and lymphocyte responsiveness. Lancet,1(7918):1246～1247.
Chavali SR, Barton LD, Campbell JB.1988. Immunopotentiation by orally-administered Quillaja saponins:effects in mice vaccinated intraperitoneally against rabies. Clin Exp Immunol,74(3):339～343.
Chen LY, Lin YL, Chiang BL.2007. Levamisole enhances immune response by affecting the activation andmaturation of human monocyte-derived dendritic cells. Clin Exp Immunol,151(1):174～181.
Chen XP, Qian LL, Jiang H, Chen JH.2011. Ginsenoside Rg3inhibits CXCR4expression and relatedmigrations in a breast cancer cell line. Int J Clin Oncol,16(5):519～523.
Cheng YJ, Zhang M, Liang QL, Hu P, Wang YM, Frank WJ, Luo GA.2011. Two-steppreparation ofginsenoside-Re, Rb1, Rc and Rb2from the root of Panaxginseng byhigh-performancecounter-currentchromatography. Separation and Purification Technology,77(3):347～354.
Cho JY, Yoo ES, Baik KU, Park MH, Han BH.2001. In vitro inhibitory effect of protopanaxadiolginsenosides on tumor necrosis factor (TNF)-alpha production and its modulation by knownTNF-alpha antagonists. Planta Med,67(3):213～218.
Cho JY, Kim AR, Yoo ES, Baik KU, Park MH.2002. Ginsenosides from Panax ginseng differentiallyregulate lymphocyte proliferation. Planta Med,68(6):497～500.
Confer AW, Adldinger HK.1981. The in vivo effect of levamisole on phytohaemagglutinin stimulation oflymphocytes in normal and Marek's disease virus inoculated chickens. Res Vet Sci,30(2):243～245.
Confer AW, Hall SM, Espe BH.1985. Transient enhancement of the serum antibody response to Brucellaabortus strain19in cattle treated with levamisole. Am J Vet Res,46(12):2440～2443.
Cox JC，Coulter AR.1997. Adjuvants-a classifieation and review of their modes of action. Vaccine,15(1):48～56.
Cuesta A, Esteban MA, Meseguer J.2002. Levamisole is a potent enhancer of gilthead seabream naturalcytotoxic activity. Vet Immunol Immunopathol,89(3-4):169～174.
D'Cruz OJ, Uckun FM.2007. Preclinical evaluation of a dual-acting microbicidal prodrug WHI-07incombination with vanadocene dithiocarbamate in the female reproductive tract of rabbit, pig, and cat.Toxicol Pathol,35(7):910～927.
Diluzio NR.1979. Lysozyme activity: an index of macrophage functional statu. Front Biol,48:447～462.
Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA.1986. Induction by IL1andinterferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule(ICAM-1). J Immunol,137(1):245～254.
Endo S, Kinoshita J, Yoshimatsu K, Kato H, Haga S, Kajiwara T.1998. Intrahepatic lymphocyte analysesand assessment of the effects of levamisole in murine hepatic metastasis model. Anticancer Res,18(2A):907～910.
Fu W, Wei J, Gu J.2006. MEF2C mediats the activation-induced cell death (AICD) of macrophage. CellRes,16(4):377～382.
Gao F, Zhang Z, Bu H, Huang Y, Gao Z, Shen J, Zhao C, Li Y.2011. Nanoemulsion improves the oralabsorption of candesartan cilexetil in rats: Performance and mechanism. J Control Release,149(2):168～174.
Gan L, Gan Y, Zhu CL, Zhang XX, Zhu JB.2009. Novel microemulsion in situ electrolyte-triggered gellingsystem for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results. Int J Pharm,365(1-2):143～149.
Ganta S, Amiji M.2009. Coadministration of paclitaxel and curcumin in nanoemulsion formulations toovercome multidrug resistance in tumor cells. Mol Pharm,6(3):928～939.
Hajnzic TF, Kastelan M, Lukac J, Hajnzic T.1999. Immunocompetent cells and lymphocyte reactivity tomitogens in levamisole-treated brain tumor children. Pediatric Hematology-Oncology,16(4):335～340.
Hashem FM, Shaker DS, Ghorab MK, Nasr M, Ismail A.2011. Formulation, characterization, and clinicalevaluation of microemulsion containing clotrimazole for topical delivery. AAPS PharmSciTech,12(3):879～886.
Hassan AB, Atta AH, Soliman RT.1989. Effect of levamisole hydrochloride on the immune response tonewcastle disease virus vaccine in chickens. Indian Vet J,66:389～394.
Hennessy KJ, Blecha F, Pollmann DS, Kluber EF.1987. Isoprinosine and levamisole immunomodulation inartificially reared neonatal pigs. Am J Vet Res,48(3):477～480.
Hirunpanich V, Sato H.2009. Improvement of cyclosporine A bioavailability by incorporating ethyldocosahexaenoate in the microemulsion as an oil excipient. Eur J Pharm Biopharm,73(2):247～252.
Hoffmann KF, James SL, Cheever AW, Wynn TA.1999. Studies with double cytokine-ceficient mice revealthat highly polarized Th1-and Th2-Type cytokine and antibody responses contribute equally tovaccine-induced immunity to Schistosoma mansoni. J Immunol,163(2):927～938.
Hu S, Concha C, Lin F, Persson Waller K.2003. Adjuvant effect of ginseng extracts on the immuneresponses to immunisation against Staphylococcus aureus in dairy cattle. Vet Immun Immunopathol,91(1):29～37.
Hunter KW, Fischer GW, Sayles PC, Strickland GT.1981. Levamisole: potentiation of primaryimmunoglobulin M antibody responses in suckling rats. Immunopharmacology,3(2):117～127.
Huang YB, Lin YH, Lu TM, Wang RJ, Tsai YH, Wu PC.2008. Transdermal delivery of capsaicinderivative-sodium nonivamide acetate using microemulsions as vehicles. Int J Pharm,349(1-2):206～211.
Huang T, Chen Y, Shou TX, Yang J, Li D.2011. Safety evaluation of diacylglycerol microemulsion inrats/mice. Agricultural Sciences in China,10(7):1117～1124.
Ince S, Kozan E, Kucukkurt I, Bacak E.2010. The effect of levamisole and levamisole+vitamin C onoxidative damage in rats naturally infected with Syphacia muris. Experimental Parasitology,124(4):448～452.
Irwin MR, Holmberg CA, Knight HD, Hjerpe CA.1976. Effects of vaccination infectious bovinerhinotracheitis and simultaneous administration of levamisole on primary humoral responses in calves.Am J Vet Res,37(2):223～226.
Ispir U, Yonar ME.2007. Effects of levamisole on phagocytic activity of rainbow trout (Oncorhynchusmykiss W.). Acta Vet Brno,76(3):493～497.
Jackson LA, Opdebeeck JP.1995. The effect of various adjuvants on the humoral immune response ofsheep and cattle to soluble and membrane midgut antigens of Boophilus microplus. Vet Parasitol,58(1-2):129～141.
Jenkins EM, Hurdle C.1989. Effect of levamisole on parenteral vaccines for swine dysentery. Br Vet J,145(6):565～572.
Jin HL, Li YJ, Ma ZH, Zhang FC, Xie QG, Gu DF, Wang B.2004. Effect of chemical adjuvants on DNAvaccination. Vaccine,22(21-22):2925～2935.
Johnkoski JA, Hsueh CT, Doerr RJ, Cohen SA.1992. Augmentation of the immune response of the murineliver by levamisole. Am J Surg,163(2):202～207.
Kale AA, Patravale VB.2008. Development and evaluation of lorazepam microemulsions for parenteraldelivery. AAPS PharmSciTech,9(3):966～971.
Kang Y, Jin H, Zheng G, Xie Q, Yin J, Yu Y, Xiao C, Zhang X, Chen A, Wang B.2005. The adjuvant effectof levamisole on killed viral vaccines. Vaccine,23(48-49):5543～5550.
Kang JH, Song KH, Woo JK, Park MH, Rhee MH, Choi C, Oh SH.2011. Ginsenoside Rp1from Panaxginseng exhibits anti-cancer activity by down-regulation of the IGF-1R/Akt pathway in breast cancercells. Plant Foods Hum Nutr,66(3):298～305.
Kaya EG, Ozbilge H, Ustundag MB, Torun YA.2011. The effects on immune response of levamisoletreatment following infection of U-937macrophages with Candida albicans. Acta Microbiol ImmunolHung,58(4):279～288.
Kensil CR, Patel U, Lennick M, Marciani D.1991. Separation and characterization of saponins withadjuvant activity from Quillaja saponaria Molina cortex. J Immunol.146(2):431～437.
Kim JY, Germolec DR, Luster MI.1990. Panax ginseng as a potential immunomodulator: studies in mice.Immunopharmacol Immunotoxicol,12(2):257～276.
Kimball ES, Schneider CR, Fisher MC, Clark MC.1992. Levamisole causes differential cytokineexpression by elicited mouse peritoneal macrophages. J Leukoc Biol,52(3):349～356.
Kong M, Park HJ.2011a. Stability investigation of hyaluronic acid based nanoemulsion and its potential astransdermal carrier. Carbohydrate Polymers,83(3):1303～1310.
Kong M, Chen XG, Kweon DK, Park HJ.2011b. Investigations on skin permeation of hyaluronic acidbased nanoemulsion as transdermal carrier. Carbohydrate Polymers,86(2):837～843.
Krakauer T, Oppenheim JJ.1993. IL-1and tumor necrosis factor-alpha each up-regulate both theexpression of IFN-gamma receptors and enhance IFN-gamma-induced HLA-DR expression on humanmonocytes and a human monocytic cell line (THP-1). J Immunol,15;150(4):1205～1211.
Larsen MW, Moser C, Hoiby N, Song Z, Kharazmi A.2004. Ginseng modulates the immune response byinduction of interleukin-12production. APMIS,112(6):369～373.
Lee YS, Chung LS, Lee IR.1997. Activation of multiple effectors pathways of immune system by theanti-neoplastic immunostimulator acidicpolysaccharide ginseng isolated from Panax ginseng.Anticancer Res,17(3):43～47.
Lee EJ, Ko EJ, Lee JW, Rho SW, Ko SY, Shin MK, Min BI, Hong MC, Kim SY, Bae HS.2004.Ginsenoside Rg1enhances CD4+T-cell activities and modulates Th1/Th2differentiation. IntImmunopharmacol,4(2):235～244.
Lee DY, Cho JG, Lee MK, Lee JW, Lee YH, Yang DC, Baek NI.2011. Discrimination of panax ginsengroots cultivated in different areas in korea using HPLC-ELSD and principal component analysis. J.Ginseng Res,35(1):31～38.
Li GF, Guo YG, Zhao DH, Qian PF, Sun JJ, Xiao C, Liang LQ, Wang HF.2006. Effects of levamisole onthe immune response and disease resistance of Clarias fuscus. Aquaculture,253(1-4):212～217.
Li RL, Sakwiwatkul K, Li YT, Hua SH.2009. Enhancement of the immune responses to vaccinationagainst foot-and-mouth disease in mice by oral administration of an extract made from RhizomaAtractylodis Macrocephalae (RAM). Vaccine,27,(15):2094～2098.
Li G.F, Liu LB, Tan YL, Liu LZ, Deng HZ, Wan H, Zhong WZ, Chen SJ.2011. In vitro effect of levamisoleon the cell viability, phagocytosis and respiratory burst of Barbel chub (Squaliobarbus curriculus)macrophages. Aquaculture Nutrition,17: e263～e270.
Li J, Xie ZZ, Tang YB, Zhou JG, Guan YY.2011. Ginsenoside-Rd, a purified component from panaxnotoginseng saponins, prevents atherosclerosis in apoE knockout mice. Eur J Pharmacol,652(1-3):104～110.
Li XR, Yue YT, Zhou YX, Fan YT, Fan C, Huang YQ, Wu F, Liu Y.2011. An oil-free microemulsion forintravenous delivery of diallyl trisulfide: Formulation and evaluation. Int J Pharm,407(1-2):158～166.
Liew FY, Cox FE.1991. Nonspecific defence mechanism: the role of nitric oxide. Immunol Today,12(3):A17～21.
Liu J, Wang S, Liu H, Yang L, Nan G.1995. Stimulatory effect of saponin from Panax ginseng on immunefunction of lymphocytes in the elderly. Mech Ageing Dev,83(1):43～53.
Lu H, Huo X, Zhang Y, Zheng M, Ma M, Zhang H, Jin M, Shen G, Jia L, Ji Y, Li X, Jin K, Jin N.2008.Enhancing effects of the chemical adjuvant levamisole on the DNA vaccine pVIR-P12A-IL18-3C.Microbiol Immunol,52(9):440～446.
MacMicking J, Xie QW, Nathan C.1997. Nitric oxide and macrophage function. Annu Rev Immunol,15:323～350.
Maey DW.1997. Vaccine adjuvants. Semin Vet surg,12:206～211.
Mayer B, Hemmens B.1997. Biosynthesis and action of nitric oxide in mammalian cells. Trends BiochemSci,22(12):477～481.
Misra CK, Das BK, Mukherjee SC.2009. Immune response, growth and survival of Labeo rohitafingerlings fed with levamisole supplemented diets for longer duration. Aquaculture Nutrition,15(4):356～365.
Mulero V., Esteban MA, Munoz J, Meseguer J.1998. Dietary intake of levamisole enhances the immuneresponse and disease resistance of the marine teleost gilthead seabream (Sparus aurataL.). Fish&Shellfish Immunology,8(1):49～62.
Narang G., Kharole MU.1995. Effect of levamisole on the efficacy of turkey herpesvirus vaccine againstMarek's disease. Indian J Vir,11(11):13～22.
Newman MJ, Wu JY, Gardner BH, Anderson CA, Kensil CR, Recchia J, Coughlin RT, Powell MF.1997.Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1gp120using saponinadjuvant(QS-21) supplemented subunit vaccine formulations. Vaccine,15(9):1001～1007.
Nornoo AO, Osborne DW, Chow DSL.2008. Cremophor-free intravenous microemulsions for paclitaxel: I:Formulation, cytotoxicity and hemolysis. Int J Pharm,349(1-2):108～116.
Obmi s ka-Domoradzka B, S Witala M, Debowy J, Garbuliński T.1995. Effects of levamisole, DTC andlow-dose lechlorethamine on humoral response of SRBC-immunized rabbits exposed to cold stress.Zentralbl Veterinarmed B,42(1-10):12～18.
O'Hagan DT, Valiante NM.2003. Recent advances in the discovery and delivery of vaccine adjuvants. NatRev Drug Discov.2(9):727～735.
Okur Nü, Apayd n, Yava o lu NüK, Yava o lu A, Karasulu HY.2011. Evaluation of skin permeationand anti-inflammatory and analgesic effects of new naproxen microemulsion formulations. Int JPharm,416(1):136～144.
Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K.1991. Properties of the novel proinflammatorysupergene "intercrine" cytokine family. Annu Rev Immunol,9:617～948.
Park D, Bae DK, Jeon JH, Lee J, Oh N, Yang G, Yang YH, Kim TK, Song J, Lee SH, Song BS, Jeon TH,Kang SJ, Joo SS, Kim SU, Kim YB.2011. Immunopotentiation and antitumor effects of a ginsenosideRg3-fortified red ginseng preparation in mice bearing H460lung cancer cells. Environ ToxicolPharmacol,31(3):397～405.
Panigraphy B, Grumbles LC, Millar M, Naqvi SA, Hall CF.1979. Antibiotic-induced immunosuppressionand levamisole-induced immunopotentiation in turkeys. Avian Dis,23(2):401～408.
Pearse MJ, Drane D.2004. ISCOMATRIX adjuvant: a potent inducer of humoral and cellularimmune responses. Vaccine,22(19):2391～2395.
Pekmezci D, Cakiroglu D.2009. Investigation of immunmodulatory effects of levamisole and vitamin E onimmunity and some blood parameters in newborn Jersey calves. Vet Res Commun,33(7):711～721.
Phan TT, Attaphong C, Sabatini DA.2011. Effect of extended surfactant structure on interfacial tension andmicroemulsion formation with triglycerides. Journal of the American Oil Chemists' Society,88(8):1223～1228.
Plevyak M, Hanna N, Mayer S, Murphy S, Pinar H, Fast L, Ekerfelt C, Ernerudh J, Berg G, Matthiesen L,Sharma S.2002. Deficiency of decidual IL-10in first trimester missed abortion: a lack of correlationwith the decidual immune cell profile. Am J Reprod Immunol,47(4):242～250.
Prow TW, Grice JE, Lin LL, Faye R, Butler Ma, Becker W, Wurm EMT, Yoong C, Robertson TA, Soyer HP,Roberts MS.2011. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev,63(6):470～491.
Pu Z, Zhang PJ, Gao YG, Hao JX, Wang YX, Li R, Yang H, Li X, Li P, Zhou DW, Zhang LX.2011. Theevaluation of contents of nine ginsenoside monomers in ginseng hairy roots by high performanceliquid chromatography (HPLC). Journal of Medicinal Plants Research,5(23):5513～5516.
Qi LW，Wang CZ，Yuan CS．2011. Isolation and analysis of ginseng: advances and challenges．Nat ProdRep,28(3):467～495.
Qu DF, Yu HJ, Liu Z, Zhang DF, Zhou QJ, Zhang HL, Du AF.2011. Ginsenoside Rg1enhances immuneresponse induced by recombinant Toxoplasma gondii SAG1antigen. Vet Parasitol,179(1-3):28～34.
Qureshi ZI, Lodhi LA, Jamil H, Nawaz M.2000. Effect of levamisole hydrochloride on serum and colostralantibody titres against foot and mouth disease virus in vaccinated buffaloes (Bubalus bubalis).Veterinarski Arhiv,70(2):59~66.
Reyero C, St ckl W, Thalhammer JG.1979. Stimulation of the antibody response to sheep red blood cells inpiglets and young pigs by levamisole. Br Vet J,135(1):17～24.
Rivera E, Hu S, Concha C.2003a. Ginseng and aluminium hydroxide act synergistically as vaccineadjuvants. Vaccine,21(11-12):1149～1157.
Rivera E, Daggfeldt A, Hu S.2003b. Ginseng extract in aluminium hydroxide adjuvanted vaccinesimproves the antibody response of pigs to porcine parvovirus and Erysipelothrix rhusiopathiae. VetImmun Immunopathol,91(1):19～27.
Rivera E, Ekholm Pettersson F, Ingan s M, Paulie S, Gr nvik KO.2005. The Rb1fraction of ginsengelicits a balanced Th1and Th2immune response. Vaccine,23(46-47):5411～5419.
Rothenberg EV, Diamond RA, Pepper KA, Yang JA.1990. IL-2gene inducibility in T cells before T cellreceptor expression. Changes in signaling pathways and gene expression requirements duringintrathymic maturation. J Immunol,144(5):1614～1624.
Sadigh-Eteghad S, Khayat-Nuri H, Abadi N, Ghavami S, Golabi M, Shanebandi D.2011. Synergetic effectsof oral administration of levamisole and Echinacea purpurea on immune response in Wistar rat.Research in Veterinary Science,91(1):82～85.
Saini SS, Sharma JK, Joshi VB, Kwarta MS.1991. Effect of levamisole on humoral immune response ofcow-calves vaccinated with Brucella abortus strain19vaccine. Indian J Ari Res,25:69～72.
Sampson D, Lui A.1976. The effect of levamisole on cell-mediated immunity and suppressor cell function.Cancer Res,36(3):952～955.
Sanadgol H, Khoshnoodi M, Mashhadi MA, Forghani MS.2011. Effect of adding levamisole onseroconversion response to hepatitis B virus vaccination in hemodialysis patients: a single-centerexperience. Iran J Kidney,5(5):338～341.
Sanz MJ, Weg VB, Bolanowski MA, Nourshargh S.1995. IL-1is a potent inducer of eosinophilaccumulation in rat skin. Inhibition of response by a platelet-activating factor antagonist and ananti-human IL-8antibody. J Immunol,154(3):1364～1373.
Seyed-Moayed Alavian MD, Seyed-Vahid Tabatabaei MD.2010. Effects of oral levamisole as an adjuvantto hepatitis B vaccine in adults with end-stage renal disease: A meta-analysis of controlled clinicaltrials. Clinical Therapeutics,32(1):1～10.
Shakeel F, Ramadan W.2010. Transdermal delivery of anticancer drug caffeine from water-in-oilnanoemulsions. Colloids Surf B Biointerfaces,75(1):356～362.
Sharma LK, Jagadish S, Mulbagal AN.1990. Effects of haemorrhagic septicaemia vaccination andlevamisole administration on the humoral response in cross-bred calves. J Vet Pharmacol Ther,13(1):23～28.
Sharma LK, Jagadish S, Mulbagal AN.1993. Effect of levamisole on delayed-type hypersensitivity incrossed calves. Indian Veterinary Journal,70(8):699～701.
Shen Q, Li X, Li WJ, Zhao XY.2011. Enhanced intestinal absorption of daidzein by borneol/mentholeutectic mixture and microemulsion. AAPS PharmSciTech,12(4):1044～1049.
Shibata H, Kimura-Takagi I, Nagaoka M, Hashimoto S, Aiyama R, Iha M, Ueyama S, Yokokura T.2000.Properties of fucoidan from Cladosiphon okamuranus tokida in gastric mucosal protection. Biofactors,11(4):235～245.
Shishu, Kamalpreet, Maheshwari M.2012. Development and evaluation of novel microemulsion based oralformulations of5-fluorouracil using non-everted rat intestine sac model. Drug Dev Ind Pharm,38(3):294～300.
Singh LDK, Rao AT.1988. Effect of levamisole and prednisolone on chicken infected with infectionsbursal disease virus. India J Ani Sci,58(5):589～593.
Sintov AC, Levy HV, Botner S.2010. Systemic delivery of insulin via the nasal route using a newmicroemulsion system: In vitro and in vivo studies. J Control Release,148(2):168～176.
Siwicki AK, Cossarini-Dunier M.1990. Effect of levamisole on the lymphocyte and macrophage activity incarp (Cyprinus carpio). Ann Rech Vet,21(2):95～100.
Srinivasa Rao TV, Mishra, SC, Jaiswal TN,1994. Effect of levamisole on complement levels in chickensvaccinated and challenge infected with infectious bronchitis virus. Indian Veterinary Journal,71,8～11.
Song Z, Wu H, Mathee K, H iby N, Kharazmi A.2002. Gerimax ginseng regulates both humoral andcellular immunity during chronic Pseudomonas aeruginosa lung infection. J Altern Complement Med,8(4):459～466.
Song Z, Moser C, Wu H, Faber V, Kharazmi A, H iby N.2003. Cytokine modulating effect of ginsengtreatment in a mouse model of Pseudomonas aeruginosa lung infection. J Cyst Fibros,2(3):112～119.
Song Z, Moser C, Wu H, Larsen MW, Johansen HK, Faber V, Kharazmi A, H iby N.2005. Ginsengmodulates the immune response via its effect on cytokine production--secondary publication. UgeskrLaeger,167(33):3054～3056.
Song XM, Bao SJ, Wu LH, Hu SH.2009a. Ginseng stem-leaf saponins (GSLS) and mineral oil actsynergistically to enhance the immune responses to vaccination against foot-and-mouth disease inmice. Vaccine,27(1):51～55.
Song XM, Zang LM, Hu SH.2009b. Amplified immune response by ginsenoside-based nanoparticles(ginsomes). Vaccine,27(17):2306～2311.
Song XM, Chen J, Sakwiwatkul K, Li RL, Hu SH.2010. Enhancement of immune responses to influenzavaccine (H3N2) by ginsenoside Re. Int Immunopharmacol,10(3):351～356.
Soppi E, Lassila O, Viljanen MK, Lehtonen OP, Eskola J.1979. In vivo effect of levamisole on cellular andhumoral immunity in normal chickens. Clin Exp Immunol,38(3):609～614.
Sun HX, Chen Y, Ye Y.2006. Ginsenoside Re and notoginsenoside R1: Immunologic adjuvants with lowhaemolytic effect. Chem Biodivers,3(7):718～726.
Sun JH, Song XM, Hu SH.2008. Ginsenoside Rg1and aluminum hydroxide synergistically promoteimmune responses to ovalbumin in BALB/c mice. Clin Vaccine Immunol,15(2):303～307.
Sun YX, Tong HB, Li MQ, Li YJ, Guan SW, Liu JC.2008. Immunological adjuvant effect of Japaneseginseng saponins (JGS) on specific antibody and cellular response to ovalbumin and its haemolyticactivities. Vaccine,26(47):5911～5917.
Sun S, Qi LW, Du GJ, Mehendale SR, Wang CZ, Yuan CS.2011. Red notoginseng: higher ginsenosidecontent and stronger anticancer potential than Asian and American ginseng. Food Chem,125(4):1299～1305.
Szeto C, Gillespie KM, Mathieson PW.2000. Levamisole induces interleukin-18and shifts type1/type2cytokine balance. Immunology,100(2):217～224.
Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA.1990. Induction of CD8+cytotoxic T cells by immunization with purified HIV-1envelope protein in ISCOMs. Nature,344:873～875.
Tian ZG, Yang GZ.1993. Promoting effect of panaxatriol ginsenoside on gene expression of humaninterleukin-1. Acta Pharmacol Sin,14(3):159～161.
Tsai YH, Lee KF, Huang YB, Huang CT, Wu PC.2010. In vitro permeation and in vivo whitening effect oftopical hesperetin microemulsion delivery system. Int J Pharm,388(1-2):257～262.
Tung NH, Yang SY, Kim JH, Song GY, Kim YH.2010. Dammarane-type saponins from the black ginseng.Bull. Korean Chem. Soc,31(11):3423～3426.
Ustünda Okur N, Apayd n S, Karabay Yava o lu Nü, Yava o lu A, Karasulu HY.2011. Evaluation ofskin permeation and anti-inflammatory and analgesic effects of new naproxen microemulsionformulations. Int J Pharm,416(1):136～144.
Vander Maaten MJ, Schmerr MJ, Miller JM, Sacks JM.1983. Levamisole does not affect the virologicaland serological responses of bovine leukemia virus-infected cattle and sheep. Can J Comp Med,47(4):474～479.
Verhagen H, DeCree J, DeCock W, Verbruggen F.1973. Levamisole and the immune response. N Engl JMed,289:1148～1149.
Vyas TK, Babbar AK, Sharma RK, Singh S, Misra A.2006. Intranasal mucoadhesive microemulsions ofclonazepam: preliminary studies on brain targeting. J Pharm Sci,95(3):570～580.
Vyas TK, Shahiwala A, Amiji MM.2008. Improved oral bioavailability and brain transport of saquinavirupon administration in novel nanoemulsion formulations. Int J Pharm,347(1-2):93～101.
Wang Y, Wang BX, Liu TH, Minami M, Nagata T, Kejima T.2000. Metabolism of ginsenoside Rg_1byintestinal bacteria Ⅱ. Immunological activity of ginsenoside Rg-1and Rh-1. Acta Pharmacol Sin,21(9):792～796.
Wang KX, Zhang LH, Peng JL, Liang Y, Wang XF, Zhi H, Wang XX, Geng HX.2005. Effect of linimentlevamisole on cellular immune functions of patients with chronic hepatitis B. World J Gastroenterol,11(45):7208～7210.
Wang X, Jin H, Du X, Cai C, Yu Y, Zhao G, Su B, Huang S, Hu Y, Luo D, She R, Luo X, Zeng X, Yi X,Wang B.2008. The protective efficacy against Schistosoma japonicum infection by immunizationwith DNA vaccine and levamisole as adjuvant in mice. Vaccine,26(15):1832～1845.
Wu JY, Gardner BH, Murphy CI, Seals JR, Kensil CR, Recchia J, Beltz GA, Newman GW, Newman MJ.1992. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1vaccine. J Immunol,148(5):1519～1525.
Xu H, Dilulio NA, Fairchild RL.1996. T cell populations primed by hapten sensitization in contactsecsitiviry are distinguished by polarized patterns of cytokine production: interferongamma-producing (Tc1) effectors CD8+T cell and interleukin (Ⅱ)4/-10-producing (Th2) negativeregulatory CD4+T cell. J Exp Med,183(3):1001～1012.
Xu L, Pan J, Chen Q, Yu Q, Chen H, Xu H, Qiu Y, Yang X.2008. In vivo evaluation of the safety oftriptolide-loaded hydrogel-thickened microemulsion. Food Chem Toxicol,46(12):3792～3799.
Yang ZG, Ye YP, Sun HX.2007a. Immunological adjuvant effect of ginsenoside Rh4from the roots ofPanax notoginseng on specific antibody and cellular response to ovalbumin in mice. Chem Biodivers,4(2):232～240.
Yang ZG, Chen AQ, Sun HX, Ye YP, Fang WH.2007b. Ginsenoside Rd elicits Th1and Th2immuneresponses to ovalbumin in mice. Vaccine,25(1-2):161～169.
Yen MH, Lin CC and Yen CM.1995. The immunomodulatory effect of saikosaponin derivatives and theroot extract of Bupleurum kaoi in mice. PhytotherRes,9(5):351～358.
Yin J, Jin H, Kang Y, Xiao C, Zhao L, Li X, Ding Z, Yang F, Zhu Q, Wang B.2006. Efficacy of modifiedlevamisole adjuvant on inactivated virus vaccine. Viral Immunol,19(3):525～535.
Yu JL, Dou DQ, Chen XH, Yang HZ, Guo N, Cheng GF.2004. Immunoenhancing activity ofprotopanaxatriol-type ginsenoside-F3in murine spleen cells. Acta Pharmacol Sin,25(12):1671～1676.
Yu JL, Dou DQ, Chen XH, Yang HZ, Guo N, Cheng GF.2005. Protopanaxatriol-type ginsenosidesdifferentially modulate type1and type2cytokines production from murine splenocytes. Planta Med,71(3):202～207.
Zhang QZ, Jiang XG, Jiang WM, Lu W, Su LN, Shi ZQ.2004. Preparation of nimodipine-loadedmicroemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int JPharm,275(1-2):85～96.
Zhang H, Cui YN, Zhu SM, Feng FQ, Zheng XD.2010. Characterization and antimicrobial activity of apharmaceutical microemulsion. Int J Pharm,395(1-2):154～160.
Zhang J, Michniak-Kohn B.2011. Investigation of microemulsion microstructures and their relationship totransdermal permeation of model drugs: ketoprofen, lidocaine, and caffeine. Int J Pharm,421(1):34～44.
Zhou ZX, Qu Y, Dou DQ, Liu FY, Huo YS, Jiao FB.2011. The ginsenoside profile of ginseng cultivatedunder mountainous forest. Journal of Medicinal Plants Research,5(3):410～419.
Zhu WW, Yu AH, Wang WH, Dong RQ, Wu J, Zhai GX.2008. Formulation design of microemulsion fordermal delivery of penciclovir. Int J Pharm,360(1-2):184～190.
Zhu J, Zhang XY, Gao F, Chen M, Huang SQ.2011. Preparation and properties of alkoxysilane/acrylatecopolymer microemulsion. Journal of Polymer Research,18(6):1991～1997.